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Abstract 
 
Background and Introduction: After many years of war, sanctions and occupation, 
Iraq health services and pharmaceutical system is struggling to improve. National 
efforts are needed to develop the current health care system. A feasibility study might 
be helpful for learning from other health care models in the world. The choice of the 
topic was influenced by the concept of the rational use of pharmaceuticals in general. 
The background for selecting the Nordic pharmaceutical model in this study was due 
to of its unique welfare focus. There could be other model options but because of the 
current location of the researcher coupled with a recent description of the Nordic 
model as a next “supermodel” in the world, the Nordic countries seem like an 
appropriate choice.  
 
Purpose: The purpose of this study is to map, from the pharmacist’s point of view, 
the possible feasibility of the Nordic pharmaceutical pricing and reimbursement 
system as a model for the pharmaceutical system in Iraq. Further to describe the 
current Iraqi pricing system and the current payment system for pharmaceuticals, 
including a description of the need for modernization and rebuilding of the 
pharmaceutical policy in Iraq. The Nordic countries pharmaceutical pricing and 
reimbursement model specifically focused on in this study is Norway. 
 
Methods: Qualitative methods and a case study were the main methods, after a 
literature review on the theme gave limited yield. Eleven semi-structured qualitative 
interviews with pharmacists were conducted and data was collected about diabetes 
treatment in Iraq as compared to Norway as a case to exemplify differences in 
availability and affordability of medications in these countries. Informants were from 
both Iraq and Norway. Iraqi pharmacists provided data for the Iraqi part of the case 
study. The data from the qualitative interviews was analyzed by using the program 
Hyper Research and, meaning condensation was used in the analysis of the 
interviews, whereas the case study is a simple comparison of publicly accessible 
pricing and reimbursement information from Norway to unpublished information from 
Iraq, in the absence of published data on the mapped variables.  
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Results: The results from the literature research show that the literature on pricing 
and reimbursement of pharmaceuticals in Iraq was meagre. The results from the 
interviews confirmed that restructuring and reforming to increase the availability of 
medications was needed in Iraq. A general reimbursement of pharmaceuticals could 
benefit Iraqi patient but the system would need adaptation to the national 
requirement and patients’ ability to pay. Finally, the diabetes data analysis showed 
the lower quality of diabetes treatment in Iraq as compared to Norway. 
 
Discussion and conclusion: This study explores the requirements of development 
in form of reimbursement in both private and public sector. The conclusion of the 
feasibility study of the Nordic pricing and reimbursement model is that in order to 
implement a Nordic model, an adaptation to the national characteristics of the users 
is needed. The Nordic model does not need to be completely copied to learn from it, 
rather some adaptation of the model is required. Further studies are needed to create 
a basis for implementing a general pricing and reimbursement model in Iraq. For 
example the prioritizing of resources in the pharmaceutical sector of Iraq need to be 
further explored. This is to support the Iraqi patients in both public and private sector 
to get better availability and affordability of medications. 
 
Keywords:  
Pharmaceutical reimbursement, pharmaceutical pricing, feasibility, Nordic, Iraq, 
Norway, pharmaceutical policy, affordability 
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Sammendrag  
 
 
Bakgrunn og Innledning: Etter mange år med krig, sanksjoner og okkupasjoner, 
sliter Iraks helsetjeneste og farmasøytiske system med å forbedres. Nasjonal innsats 
for å utvikle det nåværende helsevesenet er nødvendig. En gjennomførbarhetsstudie 
kan være nyttig for å lære av andre helsetjenestemodeller i verden. Valget av tema 
var påvirket av rasjonell bruk av legemidler generelt. Bakgrunnen for å velge den 
nordiske farmasøytiske modellen i denne studien var på grunnlag av den nordiske 
modellens unike velferdsfokus. Det kan være en annen modell for andre alternativer, 
men på grunn av den nåværende plasseringen av forskeren, kombinert med en nylig 
beskrivelse av den nordiske modellen som en neste "supermodell" i verden, virker 
Norden som et passende valg. 
 
Hensikt: Hensikten med denne studien er å kartlegge, fra farmasøytenes synspunkt, 
den mulige gjennomførbarheten av nordiske legemiddelpriser og det nordiske 
refusjonssystemet, som en modell for det farmasøytiske systemet i Irak. Samt å 
ytterligere beskrive dagens irakiske prissystem og betalingssystem for legemidler, 
inkludert en beskrivelse av behovet for modernisering og endring av den 
farmasøytiske politikken i Irak. Den Nordiske farmasøytiske prising og 
refusjonsmodell fokuserer spesielt på Norge i denne studien. 
 
Metoder: Kvalitative metoder og en sakstudie ble én av de sentrale metodene, siden 
litteraturgjennomgang på temaet ga begrenset utbytte. Elleve semi-strukturerte, 
kvalitative intervjuer med farmasøyter ble gjennomført, og data ble samlet inn om 
diabetesbehandling i Irak i forhold til Norge, for å eksemplifisere forskjeller i 
tilgjengelighet og kostnader på medisiner i disse landene. Informantene var fra både 
Irak og Norge. Irakiske farmasøyter ga data for den irakiske delen av sakstudien. 
Dataene fra de kvalitative intervjuene ble strukturert ved hjelp av programmet Hyper 
Research, en tilnærming AV BETYDNING AV EN KONDENS METODE som brukes i 
analysen av intervjuene. Sakstudiet er en enkel sammenligning av offentlig 
tilgjengelig prisings- og refusjonsinformasjon fra Norge med upublisert informasjon 
fra Irak, i fravær av publisert data på de kartlagte variablene. 
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Resultater: Resultatene fra litteraturforskningen viser at litteraturen om priser og 
refusjonen av legemidler i Irak var magre. Resultatene fra intervjuene bekreftet at 
omstilling og reformering, for å øke tilgjengeligheten av medisiner var nødvendig i 
Irak. En generell refusjon av legemidler kan være til nytte for irakiske pasienter, men 
systemet ville trenge tilpasning til det nasjonale kravet og pasientens evne til å 
betale. Diabetesdataanalysen viste lavere kvalitet på diabetesbehandlingen i Irak i 
forhold til Norge. 
 
Diskusjon og konklusjon: Denne studien utforsker kravene til utvikling i form av 
refusjon, i både privat og offentlig sektor. Konklusjonen av gjennomførbarhetsstudien 
av den nordiske prisings- og refusjonsmodellen med tanke på å implementere en 
nordisk modell, er at en tilpasning til de nasjonale karakteristika hos brukerne er 
nødvendig. En kopi av den nordiske modellen er ikke essensiell, men å innføre 
modellen og foreta en tilpasning vil være å anbefale. Konklusjonene er at videre 
studier er nødvendig for å skape et grunnlag for å kunne implementere en generell 
pris- og refusjonsmodell i Irak. Det trengs for eksempel ytterligere utforskning av 
prioriteringen av ressurser i den farmasøytiske sektoren i Irak. Dette for å støtte 
irakiske pasienter, i både offentlig og privat sektor, for å få bedre tilgjengelighet og 
lavere kostnader på medisiner. 
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Glossaries  
 
 
A/B prescriptions: The pharmaceuticals (in prescription Group A or B) containing 
narcotic and / or psychotropic substances, such as strong painkillers, antianxiety, 
pharmaceuticals for sleep etc. 
 
ATC-system: International (Anatomical Therapeutic Chemical) classification system 
for pharmaceuticals recommended by the World Health Organization (WHO). 
 
Blue prescription: A prescription form for medicines reimbursed by National 
Insurance after approved rules. (T-resept in Norwegian) 
 
 
Contribution scheme (Bidragordning in Norwegian): Benefit Scheme beyond 
reimbursement scheme. HELFO can make contributions to cover the cost of 
pharmaceuticals expenses not covered by blue prescription scheme. 
 
Deductible: (Egenandel in Norwegian) the amount the patient must pay for 
medicines reimbursed by National Insurance (reimbursement system) 
 
Defined Daily Dose (DDD):  It is a unit used in the estimation of pharmaceuticals 
consumption for international comparisons and use over time. The estimated average 
daily dose used on its main indication for an adult 
 
Dirty Job:  In Iraq, the word dirty job used to describe the misuse of the public 
system and the illegal sale of pharmaceuticals in general in addition to the other 
contracts between physicians and pharmaceutical companies, illegal sale of 
pharmaceuticals and intruders problem. 
 
Exemption card: A card for health care you get when you have paid a certain 
amount of deductibles. When having an exemption card, you can avoid paying the 
deductibles for the remainder of the calendar year. 
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Harmonized system codes: The Harmonized Commodity Description and Coding 
System of tariff, an international standardized system of names and numbers to 
classify products (chapter 30 is pharmaceutical products) 
 
Hospitals Pharmacies: A pharmacy in collocation with a hospital included in public 
health plans, and having pharmaceuticals supply to the hospital as its primary 
 
H-prescription: Prescriptions of pharmaceuticals regional health authorities have 
responsibility for financing 100%. 
 
Life expectancy at birth, (total years): This indicates the number of years a newborn 
infant would live if prevailing patterns of mortality at the time of birth were to stay the 
same throughout its life.  
   
Medicine outlets: Distribution units for prescription pharmaceuticals under the 
control of a local pharmacy, often localized in daily supermarkets. Operation of 
medicine outlets are subject government regulations. Many medicine outlets also 
have a package commission scheme with the local pharmacy, and dispense 
packages of POM from the pharmacy to the final users. This concerns Norway 
 
Pharmaceutical expenditure: covers the spending on prescription medicines and 
self –medication, often referred to OTC, for some countries. Other medical non-
durables such as syringes, bandages, etc., may be included in the total. It is also 
includes pharmacists remuneration when it is separated from the price of medicines. 
Pharmaceuticals consumed in hospitals are excluded,(on average they account for 
around 15% of total pharmaceuticals includes wholesale and retail margins and value 
added tax(OECD, 2011) . 
 
Reimbursement: Replacement or repayment / to pay back money to someone who 
has spent it for you or lost it because of you / to pay someone an amount of money 
equal to an amount that person has spent.   
 
16 
 
Regressive margin scheme: Margins (percent premium) is decreasing with 
increased purchase price. 
 
KIMADIA: The Iraqi State Company for Marketing Drugs and Medical Appliances that 
is the only Iraqi company, which is specialized with regard to importing, storage and 
distributing  of pharmaceuticals and Medical appliances and equipment’s for the 
public sector institutions in Iraq and Kurdistan (including general hospitals, clinics and 
public health centers),established in 1964. 
 
 FarmaPro: advanced software program for pharmacy retailers in Norway. It contains 
information for pharmaceuticals management, re-ordering, stock management, 
reports of sales and purchase and the pharmacy communication with other national 
actors and authorities. It generates and sends automated emails / text messages to 
preferred pharmaceutical suppliers whenever stock levels fall below predefined level 
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Prologue  
 
 
To start with, I want to explain that I have just started my career as a pharmacist in 
Norway, but I am an experienced one in my home country Iraq. There, I worked in 
different sectors in the health care system in many branches such as Manufacturing, 
Hospitals, Regulation, Marketing and Community pharmacy. This was parallel to my 
job as a pharmacist in my own community pharmacy. When I was in Iraq, medicines 
deficiency and low quality health care system was a part of my private life. I lost my 
mother  early because of Diabetes type 2 and many of my people have chronic 
diseases and  depend on lifesaving medicines and treatment such as Insulin, asthma 
medicament’s and anti-cancer therapy that can be very expensive to most of the 
patients in Iraq. The bad pharmaceutical system there is one of the most important 
factors to make simple chronic diseases a source of mortality in Iraq such as 
Diabetes type 2 and Diabetes type 1 among young people. In addition to many 
complications because of such type diseases and bad health care service such as 
incontinence problems with the old aging people and cancer patients etc. 
 
When I came to Norway, I started thinking about the difference between a patient 
with a chronic disease who lives in Norway and the one who lives in Iraq. Especially 
after my young son’s disease, He has Diabetes type 1 since 2009. I have been 
influenced personally by the economic support of the pharmaceutical system in 
Norway, especially, when my son received treatment for diabetes type 1 by the 
impressive reimbursement system and the blue prescription scheme. 
  
All this has motivated me to write my master’s thesis and to learn more about the 
differences between the countries pharmaceutical systems, and what can be helpful 
to Iraq to get better future in the pharmaceutical area. The topic of my thesis was to 
explore the feasibility of Nordic pricing and reimbursement system for Iraq.  
 
The main object is to describe and to compare pharmaceutical payment system 
including reimbursement and regulation of pharmaceutical prices in Nordic and in 
Iraq. Further to raise a question about whether the Nordic pharmaceuticals’ model 
21 
 
can be feasible in Iraq or not?  In addition to that, I want to explore what 
consequences each system could have on both the pharmacy selling behavior and 
the patients in Nordic and in Iraq. What is included in the pharmacy’s margin? How is 
the pharmacy margin decided in these countries? 
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1 Introduction  
1.1 Background for the choice of topic 
 
After decades of war, sanctions and occupation, Iraq health services and system are 
struggling to improve. National development plans are needed to support the health 
care system. Currently, there is a need for feasibility studies based on comparisons 
with other health care models in the world. Generally health care restructuring in Iraq 
is a major subject now for many health professionals. Any efforts of reform or 
restructuring must be realistic and practical according to Iraqi culture, but the main 
and the important target is to change from bad quality, even though free government 
health services, to high quality and well organized system. 
  
The background of the choice of the topic depended on the definition of rational use 
of drugs and the good pharmacy practice (GPP), sometimes the most appropriate 
therapy does not include drugs. When it does the rational use of drugs demands that 
the appropriate drug be prescribed, that it be available at the right time at a price 
people can afford, that it be available at the right time, that it be dispensed correctly 
and it be taken in the right dose at the right intervals and for the right length of time. 
The appropriate drug must be effective, and of acceptable quality and safety (WHO, 
2014a). 
 
A good pharmacy service is in place when pharmaceuticals are provided safely, in 
sufficient amounts, and with enough good quality in such a way that everyone in the 
population who needs the pharmaceutical receives it when they need it (Karin 
Wiedenmayer, 2006). It is very important to make sure that the pharmaceutical 
supply to the patients works optimally and the pharmacy sector  is able to offer all 
pharmaceuticals and services with security, like in the Nordic countries  much has 
been written about the need to improve and develop the pharmaceuticals policy in 
Iraq, and a new study  from Kurdistan confirmed this and showed that there is an 
urgent need to improve the future health system (Tawfik-Shukor & Khoshnaw, 
2010b). A comparison study is needed to help the Iraqi society to further develop the 
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pharmaceuticals pricing and payment system. The Nordic model could be an ideal 
example to compare to and to learn from. There are many efforts through meetings 
and workshops in local health care institutions in Iraq now toward the national 
development plan, especially in the health care system and pharmaceuticals 
policy(WHO, 2014b). 
 
Nowadays, many countries like to compare themselves with other countries, because 
of economic success or because of education level or because of differences in 
morbidity and mortality. 
 
In the February 2013 issue of the “Economist” magazine, the model of governance 
adopted by Nordic countries was presented  as the next “supermodel”,  the magazine 
praised the Nordic countries for avoiding the extreme inequalities which had 
disturbed America, because it was a model that was able to balance the economic 
and the social needs of society (Economist, 2013). Therefore I chose the Nordic 
pharmaceutical model as a good model to compare Iraq with. 
 
The topic choice could help to learn more and more about the positive sides in this 
part of the globe. Iraq played  a big role in the early pharmacy history, the first 
pharmacy in the world was established in Baghdad in the early 800s  (Kheir et al., 
2008), whereas the first pharmacy in the Nordic countries  was established in 
Copenhagen Denmark in 1427 and the first pharmacy in Norway was established in 
Bergen in 1595 (Flood, 1889).The development sometimes is fast and beneficial in 
one country while slower and less beneficial in another, even backwards. The country 
where the first pharmacy was established could now benefit from learning from 
countries that started the development centuries later.  
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1.2. Nordic Geography and Demography 
 
The Nordic region refers to the five Nordic countries: Denmark, Finland, Iceland, 
Norway and Sweden. The Nordic countries are located in the northern part of Europe 
and in the North Atlantic (see figure 1). The total population was close to 25 Million in 
2013 (see table 1) of which the smallest country is Iceland. The Nordic countries 
have one of the lowest population densities in the world. The mainland Denmark has 
the highest population density in the Nordic countries with 130 people per km2 (see 
figure 2). The Nordic countries have many similarities in their way of life, history, 
language and social structure. Politically, the Nordic countries do not form a separate 
entity, but they co-operate in the Nordic Council (Library, 2014). 
 
Each country with-in Nordic area has its own administrative structure which is the 
result of its organizational history including a number of often quite recent reforms at 
different scales (Grunfelder et al., 2014). Taxes have an important role in the local 
welfare system which are relatively high in the region (Norden, 2014a). 
 
Figure 1. Map of the Nordic countries. 
 
 
 
Source : (Colourbox, 2014). 
Source: Free licensed maps from (wikimedia, 2004). 
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Figure 2. Map shows the populations density in 2012. 
 
Source : Free licensed maps from (Library, 2012). 
 
The table below (see table 1) shows the demographic features for Nordic countries in 
compared with the same demographic feature to Iraq to make it easy to the reader to 
get idea about the countries included in this study 
Table 1. Demographic features for Nordic countries in compared with Iraq 
demographic features  
Country  Area 
a)
 in 
Km
2 
Total 
population in 
2013 Million 
Health 
expenditure 
indicators 
GDP/Capita 
d) 
Pharmacists 
rate /10000 
population
 b) 
Life 
expectancy at 
birth /years  
DM Life 
expectancy 
rankings
 c)
   
Population % 
of total death 
by DM
 c) 
Iraq 438,317 34207 3,900 / 4.9%
1
 2,2 70,85 9  
e)
 n.a 
2
 
Denmark 43,094 5,556,452 37.800 3,9 78.78 9 3.6% 
Iceland 103,000 315,281 38.500 0,44 71.25 14 1.7% 
Finland 338,145 5,222,114 35.900 3,1 79.41 18 1.3 
Norway 323,802 4 722 701 55.400 2,6 80.32 13 2.27% 
Swedish 40,900 9 119 423 40.900 not available 81.18 10 2.03% 
a)Source: (Nationsonline, 2014).  
b) Source:(FIP, 2012).  
c)Source: (worldlifeexpectancy, 2014).  
d) Data are in 2013 US dollars.   
e) Source:(WHO, 2011) . 
                                                          
1
 Government budget as a % 
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1.3 Characteristics of Nordic model 
1.3.1 The Nordic Co-operation 
 
The Nordic co-operation is one of the most extensive forms of cooperation between 
countries in a region, including Denmark, Finland, Iceland, Norway and Sweden. This 
type of collaboration  plays an important role in European and International 
development (Haagensen, 2013).The Nordic cooperation facilitates the sharing of 
experiences across the national borders and helps to give approximately the same 
welfare model (Norden, 2014a). 
 
Politically, the Nordic Council has 20 members from each country of the five 
countries. The official Nordic co-operation is financed principally with tax revenues 
from Denmark, Finland, Iceland, Norway and Sweden. There is a special distribution 
plan that specifies how much each country will contribute to the Nordic budget to run 
co-operation in the Nordic Council, The Nordic Council of Ministers and in the Nordic 
institutions, which receive money from the Nordic budget. This Nordic co-operation 
costs no more than about NOK 47 per head in the Nordic countries. This is cheap 
multi international cooperation .This co-operation can give the region strong support 
and force (Norden, 2014b).  
 
1.3.2 Main differences and similarities between the countries  
 
The Nordic countries share common values of equal opportunities, social solidarity 
and security for all its inhabitants, but different systems in terms of how the welfare 
policies are organized. In reality, the Nordic welfare provision is both more diverse 
and more complex, however the differences between the systems enable the Nordic 
countries to learn from and be inspired by each other’s experiences. However, on an 
overall level and compared to other regions they are more or less homogeneous. The 
Nordic welfare model is based on innovation. They tend to regenerate and renew the 
systems/or the schemes according to their need, and its flexible i.e. it is especially 
27 
 
prepared to meet new challenges  and this gave the region(Nordic region)the ability 
to balance strong welfare schemes.  
 
The Nordic welfare model is one of the most successful according to OECD’s 
(Organization for European Economic Co-operation and Development) ranking and 
classifications of countries economy and health care system. The Nordic region has 
the potential to be leader in the development of innovative solutions  in the world 
especially in health and social sectors (Norden, 2014a).There will be a range of 
differences between Nordic countries in their design and applications of health policy, 
enforcement measures and mechanisms (Magnussen, Vrangbæk, & Saltman, 2009).  
 
1.4 Pricing and reimbursement systems in the 
European Union (EU)  
Generally, effective and new treatments are more expensive for the society today 
compared to previous pharmaceutical innovations. This is acceptable to certain 
degrees when new treatments add additional life-years and/or quality to life and/or if 
the additional cost have saving effects on other health costs in the system. The EU 
member states have different reimbursement systems (payment by a third part and 
not only by the patient) of pharmaceuticals for its inhabitants for example the extent 
of reimbursable pharmaceuticals, the size of reimbursement, and the source of 
coverage  (Martikainen & Rajaniemi, 2002). 
 
To control the increasing cost of e.g. pharmaceuticals, in Europe the first institution or 
bodies for decision making for the health care evaluation were established in France 
and Spain in 1980s and Sweden in 1987. Many EU countries support these efforts by 
investing resources in Health Technology Assessment (HTA) to develop the health 
care system. A HTA is a knowledge summary based on a systematic summary of 
research concerning effect and safety and assessment of the consequences usually 
in terms of health economics of the new technology (García-Altés, Ondategui-Parra, 
& Neumann, 2004).  
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The pharmaceutical pricing and reimbursement systems established by EU member 
states are usually complex. Each country uses different schemes and policies, 
adapted to its own economic and health needs. These national systems are regularly 
revised or adjusted in order to consider the political priorities, market evolutions and 
patient needs. The variety of health care and social security systems has an effect on 
many national and international actors, including the pharmaceuticals industry, 
wholesalers, pharmacists, doctors, health insurance and mostly patients 
(Commission, 2013). 
 
The pricing of pharmaceuticals in many EU states members have the same principle. 
The price compared with the price of the same product in the other European 
countries in European economic area. For example, in the Netherland, the price 
depends on the average price in France, Germany and Belgium and in Ireland; the 
factory price must not be more than the lowest price in United Kingdom. 
 
In general, there are many criteria in reimbursement systems. The pricing of 
pharmaceuticals is the most important one, which influence the reimbursement 
process in EU states members. In these states except United Kingdom and 
Germany, the pharmaceutical is required to have reasonable price, and this will vary 
from country to country, but in the most of EU, the common method to decide the 
pharmaceutical reimbursement is depending on health economics studies, which give 
a measurement and comparison of costs and benefit of different treatment 
alternatives. The reference price system is mostly used and it will be described in 
details later in the text.  
 
Other criteria, which can affect the reimbursement process, are the renegotiation with 
pharmaceutical companies, the type of treatment, if its short periods of self-care use 
the effectiveness and the cost. The less effective pharmaceutical would be removed 
from the reimbursement list. Many EU countries defined the reimbursement of new 
expensive pharmaceuticals to restrict the reimbursement to the patients who will 
benefit most from treatment. 
 
In some EU countries, only the hospitals can supply patients with expensive 
pharmaceuticals. Some have difference system in which the pharmaceuticals would 
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be reimbursed only if a physician working for the system concerned has prescribed it. 
In others it will be reimbursed only if the doctor prescribing it is working with the 
public health care system such as in Spain (Martikainen & Rajaniemi, 2002). 
Generally the principles of the reimbursement systems in Europe can be described in  
eight points (Martikainen & Rajaniemi, 2002): 
1. The proportion of drug cost payable by patient. 
2. Basis of reimbursement calculation.  
3. The severity of illness or effectiveness of medicinal product. 
4. Reimbursement to children different from reimbursement to adults. 
5. Patient’s wealth. 
6. Special patients’ groups system. 
7. Ceiling set to patient’s payments. 
8. Reference price system.  
The methods of pharmaceuticals reimbursement and pricing in EU countries are 
different. According to national health care policy but basically to get an effective 
reimbursement ,all the methods must be transparent, flexible to ensure the rapid 
access to the new treatment ,strong enough to evaluate the clinical benefit and 
economic impact, and it’s easy to use by different actors (Kanavos, Vandoros, Irwin, 
Nicod, & Casson, 2011). 
 
1.4.1 Pharmacy market 
The EU member countries plus Norway and Iceland are, as regards the retail 
distribution of pharmaceuticals, generally divided into two groups of countries: the 
“deregulated” countries such as England, Ireland and the Netherlands that have been 
liberals for decades with further initiatives for more competition in rather recent times, 
whereas the regulated community pharmacy systems of Norway and Sweden were 
liberalized in 2001 and 2009 respectively. All the regulated countries surveyed 
(Austria, Denmark, Finland and Spain) have statutory establishment rules ,usually 
based on demographic and geographic criteria, allow only pharmacist to be the (key) 
owners of community pharmacy and do not permit the forming of pharmacy chains 
(Vogler et al., 2012). 
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1.5 The Nordic pharmaceutical pricing and inclusion 
of new medications in their reimbursement system 
First a brief introduction is given. Thereafter, the Norwegian system will be described 
in depth and at the end; a minor comparison is done with the other countries. 
 
The Nordics countries have very developed HTA systems. In this study, the focus is 
only on the evaluation of pharmaceuticals.  All the Nordics countries have specific 
and professional HTA bodies, which have different roles and responsibilities (see 
table 2). HTA bodies, which have responsibility about the reimbursement and pricing, 
are different from country to country. All the five countries have a specific institutions 
and advisory bodies  (Sorenson, Drummond, & Kanavos, 2008).The Nordic countries 
have dedicated HTA bodies that have desperate roles and responsibilities (see table 
2). This groups of professionals involved in reimbursement and pricing decision 
including physicians ,health economists , pharmacists , patients groups 
representatives(patients organizations) and manufacturers (Sorenson et al., 2008). 
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Table 2. Table1 Institutions and advisory bodies responsible for HTA activities 
(Decision maker).  
Co
u
n
tr
y HTA bodies Size of reimbursement by third part Governance  of 
topic selection  
Criteria for topic 
selection & 
assessment 
D
e
n
m
a
rk
 Reimbursement 
committee\Danis
h Center for 
Evaluation and 
Health 
Technology 
Assessment 
(CEMTV) 
The majority of POM are reimbursed  
automatically 
OTC pharmaceutical reimbursed 
reimbursed for specific diseases or to 
pensioners in general. 
DKMA advised 
by the 
reimbursement 
committee 
Therapeutic value of 
the pharmaceutical 
and at increasing 
frequency ,its 
financial applications 
and health economic 
evaluation 
Fi
n
la
n
d 
 Pharmaceutical 
Pricing 
Board(PPB)/Finn
ish Office for 
Health 
Technology 
Assessment 
(FinOHTA) 
Basic reimbursement 42% 
Lower special reimbursement 72% 
Higher special reimbursement 100% 
Additional reimbursement after 
reaching annual limit to co-payments  
Co-payment depending on 
reimbursement  category 
(58%/28%/€3 per medicine /€1,50 per 
medicine ) 
FinOHTA and 
STAKES(Nationa
l Research and 
Development 
Center for 
Welfare and 
Health) 
Therapeutic benefit 
,CE, budget impact 
,public health impact 
,service requirements 
and social 
/legal/ethical 
consideration 
(FinOHTA) 
Ic
e
la
n
d 
 Ministry of health 
(MoH) and 
Sjukratryggingar  
(SI)  
The General reimbursement size 
classified according to ATC 
classification (coding) into: * = Fully 
reimbursed,   B = low co-payment for 
children, elderly and disabled, E = 
general copayment and 0 = no 
reimbursement (for example 
antibiotics, contraceptives).  
Individual reimbursement based on 
applications 
National 
reimbursement 
codes set by the 
MoH, paid by the 
national 
insurance  
The reimbursement 
decision depending 
on the disease area 
and cost of 
pharmaceuticals. 
Restrictions can be 
imposed according to 
indication ,severity of 
illness and patient  
population 
OTC is unregulated 
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N
o
rw
a
y 
 Pharmaceutical 
Pricing 
Board(PPB)/Nor
wegian 
Medicines 
Agency (NoMA) 
National Reimbursement Codes  
Green box: include preapproved 
prescriptions. 
Yellow box: Include preapproved 
prescriptions subject to particular 
conditions. 
Dark yellow box: include individual 
application, approval by HELFO 
subject to particular conditions. 
NoMA in 
consultation with 
National 
Advisory 
Committee for 
Drug 
Reimbursement 
y  
The Norwegian 
reimbursement 
system characterized 
as disease and 
consumption based  
 
Sw
e
de
n
  The Dental and 
Pharmaceutical 
Benefits Agency, 
TLV Swedish 
Council on 
Technology 
Assessment in 
Health 
Care(SBU) 
Reimbursement depends on yes /no 
decision for inclusion on positive list. 
In exceptions conditional coverage 
given for particular applications or 
conditions. 
Ministry of health 
and Social 
Affairs ,Swedish 
Parliament, 
various health 
care 
organizations, 
health experts 
and SBU  
Therapeutic benefit, 
patient benefit, 
CE(cost 
effectiveness),availabi
lity of therapeutic 
alternatives 
Source of the table above: Compiled by the author, based on the survey done in the 
study Impact of pharmacy deregulation and regulation in EU, and adding information 
from Martikainen & Rajaniemi, 2002; Sorenson et al., 2008; WHOCC, 
2011.(Lyfjaverðskrá, 2015) and (Sjúkratryggingar Islands, 2015) 
 
1.6 Pharmaceutical reimbursement in the Nordic 
countries 
The Nordic health care system is based on a principle of free and equal access for all 
citizens (Festøy & Yu, 2011),and the pharmaceutical reimbursement system was one 
of the most important tools to realize this principle. Generally, the health care system 
in Nordic countries has more similarities than differences and in all Nordic countries, 
more than 80% funding from public sources. In Iceland, the central government is 
providing the most of the health service funding while the county council in Denmark, 
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Norway and Sweden are central. In Finland, municipalities are the provider of health 
care services (Kristiansen & Pedersen, 2000). 
 
Most pharmaceuticals are reimbursed by the state, funded by the comprehensive tax 
systems, and the patient co-pay or pay some medications by themselves (types of 
medications and amount of co-payment varies between the Nordic countries). One of 
the goals, which some of the Nordic countries intended to achieve through the 
deregulation of pharmacy sector, was to increase the accessibility of 
pharmaceuticals, and to keep the quality of the pharmacy service in high level. This is 
initially due to the good qualification of pharmacists, a professional self-
understanding as a part of the health care system and quality standards established 
by the pharmacy owner. On the other hand ,the goal of the deregulation in the 
pharmacy sector is usually to increase the accessibility of pharmaceuticals and to 
reduce of the price of (OTC) medicines and being part of the overall health care 
system ,the pharmacy sector is not typical market and should therefore not be left to 
market force alone (Vogler et al., 2012). 
 
1.7 Norwegian regulatory framework and system 
organization 
The essential national laws regulating the pharmaceutical market in Norway are the 
pharmacy law which regulate the rules for pharmacy and the health care professional 
Law 2000−06−02 nr 39 (Lovdata, 2014b) which regulates the health care 
professionals duties and rights, and the pharmaceutical law which regulate the 
pharmaceuticals market , Law nr 1992−12−04 number 132 (Lovdata, 2014a). 
 
Norway is involved in market authorization ( MA) of pharmaceuticals through EEA 
agreement manufacturer is issued with a marketing authorization i.e. permission to 
sell the medicine (Legemiddelverket, 2014b). 
 
According to the pharmaceutical law, the most important goal for Norwegian 
pharmaceutical policy is: 
1. To obtain suitable/rationale use of pharmaceuticals. 
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2.  Medicinal products shall be used correctly in both medical and economic 
terms. 
3. Patients shall have secure access to effective medicinal products, regardless 
of their ability to pay for them and pharmaceuticals shall have the lowest possible 
price (Festøy & Yu, 2011). 
 
The figure below (se figure 3) shows the decision maker process and the authorities 
in this area. 
 
Figure 3. Norway - The decision-making process for reimbursement of 
pharmaceuticals. 
 
 
. 
NoMA = Norwegian Medicines Agency 
1a = approve, 1b = reject, 2 = pass to the Ministry of Health and Care Services 
(HOD), 3 = bring the case before Parliament in the form a Budget Bill 
Source: NoMA 2011  
Source: Reprinted with permission from  author Sabin Volger (Festøy & Yu, 2011)  . 
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1.8 The pharmaceutical system in Norway 
 
Norwegian Medicines Agency (NoMA) uses the national system for the introduction 
of new pharmaceuticals within the specialist health service. Norway is involved in 
market authorization (MA) through EEA agreement. Manufacturers were issued with 
a marketing authorization i.e. permission to sell the medicine  (Legemiddelverket, 
2014b). 
 
In Norway, the administrative organ for pharmaceutical is the NoMA. NoMA has 
direct supervision of production, clinical trial and marketing of pharmaceuticals, the 
supply chain, regulation of prices and trade conditions of pharmacies. NoMA was 
established in 2001.The ministry of health and care services (Helse og Omsorg-
department, HOD) has the legislative authority. NoMA is subordinate to HOD. NoMA 
is responsible for pharmaceutical marketing authorization, classification, pricing, 
reimbursement and providing information on medicines to health care professionals 
and the public. 
 
HELFO (The Norwegian Health Economics Administration) managed the 
reimbursement for the individual patient for pharmaceuticals outside the general 
reimbursement or indications not covered within the general reimbursement 
schemes. All major international pharmaceutical companies are represented in 
Norway. In Norway, there are two sources of pharmaceutical import; 
1. Countries inside the European Economic Area (EEA) 
2. Countries outside the European Economic Area (EEA) 
The first group import are all the wholesalers have permission to import from them 
but the second area (from outside EEA) this type of pharmaceuticals import needs 
additional special license from NoMA (Legemiddelverket, 2014b). 
 
1.8.1 Pricing and margins of pharmaceuticals in Norway 
NoMA is responsible for the organization of pricing. NOMA is in charge of pricing 
decision for individual medicines and sets the more specific guidelines for price 
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determination. NoMA sets maximum prices for all prescription only medicines (POM) 
at the pharmacy purchasing price level (PPP). Differences are made between new 
pharmaceuticals (Norway use the international reference pricing scheme) without 
generic competition and generics (here after a model called the stepped price 
model).  
 
However, OTCs and veterinary pharmaceuticals have free pricing. Each POM is 
given maximum prices by the NoMA. NoMA also sets maximum prices for all POM at 
the pharmacy purchases price PPP-level. The maximum price is adjusted in 
accordance to external international reference pricing. Generally the Norwegian 
maximum prices are based on the average of the three lowest PPP in Sweden, 
Finland, Denmark, Germany, United Kingdom, Nederland, Austria, Belgium and 
Ireland (Festøy & Yu, 2011). 
 
The Market Authorization Holder (MAH) has to apply for a maximum price before 
entering the market. The maximum prices have been re-evaluated yearly by NoMA. 
The pharmacy retail price is regulated by a maximum pharmacy mark-up set by 
NoMA. This system is regulated by law, in the Norwegian act on medicinal products 
(NoMA, 2014b). 
 
The maximum price (PPP) +pharmacy Mark-up add= the maximum retail price (PRP)  
 
The pharmacy margins in Norway are regulated by NoMA according to the regulation 
on medicinal products §12-13. There is maximum pharmacy margins applied to all 
price regulated medicines including the reimbursed and non-reimbursed 
pharmaceuticals. The pharmacy margins scheme is regressive. The maximum 
margins to POM which have purchase price from 200 NOK \24€\ 29$ have maximum 
margin 3% in 2014, the POM with purchase price 0-200 NOK have maximum margin 
in pharmacy 7% only in 2014, the scheme is regressive. The fixed margin per 
package in 2014 is 25 NOK and 10 NOK \1,2 € for addictive medicine and narcotic 
be added in pharmacy (Legemiddelverket, 2014a). 
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1.8.2 The stepped price model 
For generics there is a special model the stepped price model (trinnpris modellen) it 
was introduced on 2005 to decrease the cost of the national insurance scheme and 
patients related to the use of generic medicines. The pharmaceuticals prices are 
reduced systematically by pre-defined rates. The reduction occurs after the 
pharmaceutical product has lost patent production and has exposed to generic 
competition (Festøy & Yu, 2011). 
 
The stepped price is the maximum price reimbursed by the national insurance 
scheme or the price the patients pay for a pharmaceutical product that is associated 
in the reimbursement scheme system. NoMA publishes a list of generic substances 
and current prices (NoMA, 2014b). 
 
The maximum reimbursement price for a generic substance is defined as a 
percentage of the maximum retail price (PRP) of the original pharmaceutical product 
at the time was opened to generic competition. Three steps minimize the 
reimbursement price at the first 12 months of generic competition. The reduction rate 
depends on the yearly sale of the product:  
 
• The first price cut happens when generic competition apiarists about 35% of 
the original price. 
• The second price cut is preceded six months after generic competition has 
occurred 59%-81%. 
• The third step is viable 12 months or more after the time of the second step, 
69%, 86% and 90%. 
 
According to the changes in stepped price system, and the pharmacy mark-up 
scheme in 1st January 2014.This step price system also applies to the parallel 
pharmaceuticals import3 (Legemiddelverket, 2014a). 
In Norway, the pharmaceutical product is delivered in both small and large packages; 
the pharmacy is obliged to deliver both small and large packages to a retail price 
                                                          
3
 It means that a pharmaceutical that has already Norwegian authorization, imported from a country within the 
European Economic Area other than the pharmaceutical company traditional channel 
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equal price to the stepped price. The wholesalers are obliged to offer the pharmacies 
medicines that enable them to fulfill these obligations (Festøy & Yu, 2011).  
 
1.8.3 Reimbursement system in Norway 
Reimbursement (payment by third part and not only by the patient) in Norway can 
generally be said to be based on two main fundaments:  
 
1.  Fundaments concerning medical needs and solidary in the population: everyone 
should have the same access to necessary medicines regardless of their ability to 
pay. 
2. Fundaments concerning rationality: it should support rational and cost effective use 
of medicines as an instrument to ensure development in healthcare system. 
 
Reimbursement is assorted only for “long-term” medication for chronic diseases, 
determined as more than three months of medication per year. It does not cover 
short term therapy such as antibiotics, antiviral, pain analgesics (see table 3). 
 OTC (Over the counter products) are in general exempt from reimbursement (Festøy 
& Yu, 2011). 
 
The people in Norway cannot usually get expenses covered, but generally, there is a 
rule of thumb that that medicine must be: Marketed in Norway and 
Prescription printed by doctor for POM. 
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Table 3. List of pharmaceuticals that have exempted from the general 
reimbursement scheme in Norway. 
 
Contraceptives 
Drugs for alzheimers disease 
Drugs for bacterial infection 
Drugs for prostate complains 
Drugs for viral infection (antivirals) 
Estrogens and testosterone preparations 
Growth hormones 
Medicinens for allergiens 
Medicines for disinfection of skin 
Medicines for fungal infections (antifungal) 
Medicines for pain ( the pain killer) 
Medicines for smoking cessation 
Prescription medicines and commodities addictive drugs 
Tablets for erectile dysfunction (such as Cialis, Levitra, uprima, Viagra) 
Vaccines 
Vitamins and minerals 
Source: (HELFO, 2014). 
 
The general reimbursement scheme, insure that the patient can get part of the 
medicine cost, which are covered by the state when having severe and chronic 
diseases. This scheme includes the pre-approval pharmaceuticals. The pre-approval 
pharmaceuticals are described by NoMA in a list of all the items. In this pre-approval 
medicine list can be prescribed directly by the physician as a general reimbursed or 
(blue prescription). The pharmaceutical company with market authorization can apply 
for preapproved reimbursement (general reimbursement). For further information 
see(HELFO, 2014). 
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1.8.4 Reimbursement Schemes 
The statutory framework for the reimbursement is the social service act and 
regulation on medicinal product (Festøy & Yu, 2011).  
In Norway, there is no schedule 1 in reimbursement system. 
 
-Schedule 2 (§ 2) Needs that the pharmaceutical has been assented for 
reimbursement by the authorities, be reimbursed automatically. (Pharmaceuticals on 
the reimbursement list, which cover specific diagnosis for long term more than three 
months treatment). 
-Schedule 3a: (§ 3a) this schedule requires a formal application for each patient for 
pharmaceuticals other than those under schedule 2, 4 and 3b. For long-term 
treatment more than 3 months (individual reimbursement), HELFO is responsible. 
 
-Schedule 3b (§ 3b) require a formal application for each patient. This schedule can 
be given to pharmaceuticals used to treat rare diseases and for long-term treatment 
(more than three months). Individual reimbursement is HELFO’s responsibility. 
  
-Schedule 4 (§ 4) given to pharmaceuticals used to treat severe communicable 
diseases, such as: tuberculosis, syphilis, HIV/AIDS). The reimbursement rate is 
100% in this schedule (Festøy & Yu, 2011). 
 
1.8.5 Reimbursement schemes to individual drug users. 
 
The White Prescription 
 
The pharmaceuticals prescribed or printed on white prescriptions must in principle be 
paid fully by the patients. The most common exceptions are certain drugs for certain 
diseases or certain patient groups, such as the pills to young girls some medicines to 
rheumatoid arthritis and pharmaceuticals to conscripts. But the Contributions scheme 
( Bidragsordning in Norwegian) can partially recover the cost of pharmaceuticals in 
some cases on white prescriptions, regardless of disease. This is called contribution 
scheme. It can be given contribution to costs of healthcare that would otherwise not 
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to be covered by the national insurance act or other laws. The Contributions scheme 
can give the patient 90% refund of expenses exceeding 1695,- NOK (2014) of 
pharmaceuticals on white prescriptions regardless of disease(HELFO, 2014).  
 
Railway personnel 
 
The patients who are members in the railways / train ways (in Norwegian 
Jernbanepersonalets) Health fund, spouse and children under 18 have the right to a 
50% refund on a number of drugs on white prescriptions. Exceptions are drugs 
against obesity, hair loss, contraceptives, potency, and agents in smoking cessation 
and assisted reproduction. The patient must show case health card at the pharmacy 
 
Military prescriptions  
 
Conscripts are reimbursed expenses to a number of drugs certain conditions: The 
scheme also applies to civil, home guard, and civil defense. There is no user fee at 
the pharmacy when these requirements are met. In this scheme, the doctor writes out 
blue prescription regardless of whether the drug goes blue prescription or not and the 
reimbursement shall be “conscript”. Military doctor required to write the prescription. 
There are some pharmaceuticals which are not covered by this scheme: Nutrition 
supplement , vitamins and minerals, pharmaceuticals for potency, hair products 
cosmetic treatments (HELFO, 2014). 
1.8.6 Reimbursement arrangements for some Pharmaceuticals on 
white prescriptions. 
Contraceptives (P-prescriptions) 
Girls between 16 and 19 years are covered 106 NOK for three months’ supply of 
contraceptives pill. Contraceptive patches, Depo-Provera and vaginal ring. If the 
products cost over 106 NOK, the young girl must pay it exceeds 106 NOK. The 
scheme applies from the month after the young girl turn 16 years on month before 
turning 20. 
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H prescriptions (health authority) 
Prescriptions are white prescriptions in part costly medicines before were written in 
blue prescription applies TNF inhibitors, there are pharmaceuticals used for arthritis, 
ankylosing and psoriatic arthritis. From 2014 comes this scheme also some cancer 
drugs, drug user get covered 100% of the cost and the patient will not pay the 
deductible when the prescription is written out by a doctor on health authority or 
physician agreement with health trust.(Mostly prescriptions from special 
hospitals)(HELFO, 2014). 
1.8.7 Exemption cart 
The exemption cart ( called Frikort in Norwegian) is a cart or  a document ,the patient 
can get it when he paid a certain amount in users fees and when the patient get this 
type cart ,he don’t need to pay any fee the remaining of the year. There are two types 
card and they apply different services;  
The card for user fee group 1: This group covers approved user fees, physician, 
psychologist, in outpatient clinics and x-ray institutions, patient travel and 
pharmaceuticals and pharmaceutical appliance on blue prescription. The patients 
receive an exemption card automatically within three weeks once the patient has paid 
over 2185 NOK in deductibles in 2015. 
The card for user fee group 2: This card approves for treatment by a 
physiotherapist, some forms of dental diseases, stays in rehabilitating clinics and the 
treatment arranged by Oslo University hospital - Rikshospitalet H. If the patient 
paying more than 2670 NOK in approved deductibles for such treatment by 2015, 
The patient intended to get an exemption card for the user fee group 2 (HELFO, 
2014). 
1.8.8 Wholesaler’s re-payment 
Wholesalers are regulated in the Norwegian act on medicinal products. Wholesalers 
are companies in Norway who carried out wholesaling business. To carry out 
wholesaling business in Norway, the company must obtain approval from NoMA 
(Legemiddelverket, 2014b). 
 
43 
 
There are three big wholesalers in Norway which providing all the pharmaceutical 
products to the market relating to the European pharmaceutical distribution 
companies ,each of these wholesalers have been completely integrate with their own 
pharmacy chain ,those wholesalers are : 
1. Norsk Medicinal depot (NMD), which are owned by Celesio AG, with market 
share of 47%. 
2. Apokjeden AS (Apotek 1 Gruppen AS), which are owned by Tamro OYJ with 
market share of 28%. 
3. Boots Norge AS, which are owned by Alliance Boots Plc. 
 
The wholesale margins are not regulated in Norway, but the average was 7% in 
2010(NoMA, 2014a). 
1.8.9 The pharmacy retailing 
The retail business for pharmaceuticals in Norway encompasses pharmacies. 
Retailing in Norway is defined as distribution and sales of pharmaceuticals to the 
public including the health institutions and other users of pharmaceuticals. In Norway, 
the act on pharmacy requires two licenses, a license to own a pharmacy (Proprietors 
license/possessor license) and license to run the pharmacy. Only pharmacies or 
medicinal outlets (control by pharmacists) may carry out retailing of pharmaceuticals 
products, exception for pharmaceuticals intended for technical or scientific use, or 
non-medical use, for manufacturer’s and certain non-prescription pharmaceuticals to 
be sold by other retails than pharmacies. 
 
Retailing of pharmaceutical in Norway can be to the professional direct users such as 
physicians, dentists, and veterinary i.e. directly to the professional end users. NOMA 
is responsible for maximum price decision on POM. The agency evaluate and decide 
whether a pharmaceutical should be reimbursed by the national insurance scheme 
(Legemiddelverket, 2014b). 
Now a description follows of the system in Iraq. This section is short as compared to 
the Nordic countries section because of the deficiency in published literature and the 
limited availability in literature search regarding the Iraqi pharmaceutical system and 
the pharmaceutical pricing policy. 
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1.9 Iraq geography and demography 
In the 8th century AD, Iraq introduced the first privately owned community pharmacy 
in the world where the pharmacy first became independent of medicine. This start 
was in Baghdad the capital of Iraq (Kheir et al., 2008). Iraq is a Middle Eastern 
country with a population about 32 million. Arabic is the first language and Kurdish is 
the second official language of Iraq (se figure 4). 
 
Figure 4. Map of Administrative division of Iraq and Iraq location. 
 
 
Source: colure box, 2014 
 
Iraq has the fifth largest proven oil reserves of any country (after Venezuela, Saudi 
Arabia, Canada and Iran), whereas Norway is number 24. The oil productions 
increased after the fall of Saddam Hussein in 2003. The oil is concentrated in Shia in 
the south and Kurdistan in the north, with Sunni regions to the west notably lacking in 
oil wealth(CIA, 2014). 
1.9.1 Context remarks for the Iraqi crisis 
The war situation is seriously severe in Iraq now and probably it’s going to get worse 
before it gets better. An Iraqi author, quoted last year in the Independent, can 
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probably be said to speak for many Iraqi people: “When I read articles about the Iraqi 
crisis now on different websites, I get worried about many things in my mind, my past 
memories and my future in my country, especially when I read that” the old partition 
of the middle east is dead”(Independent, 2014). . 
 
The current Iraq crisis started in early June, when a group of extreme terrorists who 
called themselves as “Islamic State of Iraq and Syria or Levant “(ISIS /ISIL) which 
occupied large part of Syria already and now the occupied a large part of the north of 
Iraq, including the major city of Mosul, but originally the conflict has roots in Iraq’s 
complicated history.Iraq’s three-way demographic divide is not the reason on to this 
crisis but it is a huge part of it.  
 
In the map we can see three major group in Iraq, the largest are the Iraqi’s Shia 
(Shi’ism is a major branch of Islam), the Shia Arab are the main group there who live 
in south mostly. The second group are Sunni Arabs who live in the north and west 
Baghdad is mixed with Sunni and Shia. North (the far north) is Kurdistan. The ethnic 
Kurds are mostly Sunni but their ethnicity characterizes them and divides them from 
the Arab Sunni. Nowadays and after the war, the Shia majority dominates the Iraqi 
governments. The Sunni thought that they are underserved. The ISIS are the 
extremist Arab Sunni group that has taken over a major fraction of the country (se 
figure 5), which describe the Iraqi crisis in 2014. 
 
The Kurds who suffered under Saddam Hussein have been encouraged to get 
advantage of the recent crisis to grant them greater autonomy in Kurdistan. The 
history of Iraq is known but the current crisis that affects my study. 
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Figure 5 Iraq crisis map.  
 
 
 
 
 
 
In the map above (figure 5), ISIS appears to have handed control over to local Sunni 
groups. ISIS is originally supported and established by an Islamism group so extreme 
that they were kicked out of al-Qaida(Economist, 2014). The civilian casualties in Iraq 
have increased dramatically in June 10-12th   2014. ISIS captures Mosul and this 
crisis started following that event. The United Nations reported that the fighting in Iraq 
displaced over 1 million people or about 3% of the country’s population and the other  
Sunnis who are under the control of ISIS are worried about how their life under ISIS 
would be. The civilians begin cooperating with Iraqi government to find a solution(UN, 
2014). 
 
All that influenced my research drastically. 
 
 
Se the source down  
The pink shaded area controlled by Iraqi government 
The gray shaded area controlled by the Islamic State (IS, ISIS, ISIL) 
The yellow shaded area controlled by Iraqi Kurds 
Source:(Wikipedia, 2015). 
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1.9.2 The Kurdish region in Iraq 
Kurds are ethnic groups that have their own language and culture that lives in 
minorities in Iraq, Syria, Turkey and Iran. They have been fighting for their own 
country for more than a century.  They have taken autonomy for themselves in Iraqi 
Kurdistan region. Kurdistan Regional Government (KRG) is semi-autonomous and 
governs the three big provinces of Sulaymaniyah, Erbil and Duhok north for 
Baghdad. The Kurds have independent parliament, Prime Minister and president 
(Tawfik-Shukor & Khoshnaw, 2010b).  
 
The Kurdistan region in Iraq has a big hope to be the best in health care. The 
Kurdistan patients are luckier now than the other Iraqi patients, because of the rapid 
development in health care services general and Erbil become the country medical 
capital. Many Iraqi patients seek treatment their instead for outside Iraq (Report, 
2013).  
 
In Kurdistan, the pharmaceutical improvement was very fast and in the right way. 
However, it was just import for pharmaceuticals and a high percentage was of bad 
quality. Now this problem is partially solved. Two Kurdish private pharmaceuticals 
companies, Awamedica and Pioneer, have been established, to provide high quality, 
low cost medicines for the region. In addition to that, there are many efforts of the 
pharmacists Union in Kurdistan (pharmacist syndicate), the chairman for pharmacists 
for monitoring and standardizing of pharmaceutical pricing in all the private 
pharmacies. This system will probably help to remove the differences in pricing 
between pharmacies. In addition this make Kurdistan to increase the self-sufficient in 
terms of pharmaceuticals supply(IIG, 2014). 
 
1.9.3 Characteristics of Iraqi health care model 
In Iraq, there is no private health insurance. However, the public service, public 
health insurance, social insurance, or other sickness fund does not provide sufficient 
medicines coverage to get complete treatment for patients. There are no co-
payments for or fee for pharmaceuticals. The whole population is covered by a public 
health service, public health insurance or social health insurance (WHO, 2011). 
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1.9.4 Regulatory framework in Iraq 
There are no legal provisions/laws, establishing the responsibility of the medicine 
regulatory authorities (MRA). There is no law, or act that provides power and 
responsibility to a MRA in Iraq. There are ministerial orders, relevant laws , but not 
one direct and distinct document that regulates the work of a MRA (WHO, 2011). 
 
In Iraq the Ministry of Health (MoH) is a federal headed by a health care minister in 
Baghdad (the capital for Iraq), The Central Government, and the Ministry was 
established in 1956. A separate Ministry of Health was established for Kurdistan (the 
Kurdish region), Regional Government, with much the same structure. Kurdistan 
Medical Control Agency (KMCA) was established in 1992 (Al Hilfi, Lafta, & Burnham, 
2013). Basically, there are two MoH in Iraq ,the Federal MoH in Baghdad and The 
Regional MoH in Erbil KMoH, Kurdistan and 19 provincial Departments of Health 
(DoH)(one in each provinces and two in Baghdad) (E. WHO, 2013). 
 
In KMoH, there is a similar description of weak health systems governance and 
fragmented services. The organizational structure of KMoH is a minimized Iraqis 
wider national system and has the same key  poorly designed characteristics 
features: (centralized, politicized, non–transparent, disorganized, with no clear 
governance, regulatory, financing or accountability framework, let alone vision or 
goals (Tawfik-Shukor & Khoshnaw, 2010b). 
 
KMoH in Erbil is accountable to Kurdistan Parliament’s and founded by Kurdistan 
Treasury. Theoretically, KRG budget is obtained from Baghdad government (Ministry 
of Finance) through transfer payment equivalent to 17% of oil revenues (se figure 6) 
(Tawfik-Shukor & Khoshnaw, 2010b).  
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 Figure 6. Health system structure and governance in Kurdistan.  
 
 
 
 
 
 
 
In the figure above, the relation between KMoH and IMoH is characterized by 
standoffs rather than cooperation. The relation  with Baghdad attempting to curtail 
Kurdistan’s autonomy by withholding or delaying funds, restricting pharmaceutical 
supplies in public sector,(many of which are either not required or near expiry, due to 
the Iraqis inefficient federal clearing house) and entry of Non-Governmental 
Organizations(NGOs).It seems to that KRG is left at the mercy of Baghdad’s choices 
(Tawfik-Shukor & Khoshnaw, 2010b). 
 
In the north ,the Kurdish Regional Government in Erbil developed its own budget and 
management process which was similar to the one in Baghdad (MoH).Staffing of 
health facilities in the Kurdish area was supported and added by immigration of 
doctors and nurses fleeing from elsewhere in Iraq(Burnham, Lafta, & Doocy, 2009). 
 
The State Company for Marketing Drugs and Medical Appliance (KIMADIA), until 
2004,was the state drug and medical appliance supplier and the main importer and 
distributor of drugs and medical equipment for all Iraq. KIMADIA now supplies only 
the public sector(E. WHO, 2013). 
Source :Reprinted with permission  from the author by e-mail (Tawfik-Shukor & 
Khoshnaw, 2010a). 
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The directorate of technical affairs in the ministry of health (MoH) in addition to the 
state owned public pharmaceutical insurance and distribution company (KIMADIA) 
and the syndicate of pharmacy play the functions as a MRA. It is a part of the MoH 
within different functions outline, such as quality control of pharmaceuticals imported 
and produced, marketing, licensing, market control. Marketing authorization 
(registration for all pharmaceuticals on the market is required). In 2011 there were 
7000 pharmaceutical products registered in Iraq(WHO, 2011). 
 
 Generally, there is no legal or statutory decision on pricing of pharmaceuticals in the 
private sector. The state does not run an active national pharmaceutical price 
regulating system for retail price. Price availability and affordability of key medicines 
are not managed in the last five years. Iraq does not oblige duties and taxes on 
imported active pharmaceuticals ingredients (APIS) and not on the ready import 
packages. Pharmaceuticals are not subjected to taxes(WHO, 2011). 
 
1.9.5 Pharmaceutical financing 
In theory, all Iraqi receive health care and medicines either free of charge or for a 
symbolic nominal fee of (500 Iraqi Dinar (ID) which is equivalent to US $ 0,43 and to 
NOK 3,32)4Concessions are made for certain groups of patients to receive medicines 
free of charge: 
1. Patients who cannot afford them 
2. Children under five 
3. Pregnant women 
4. Elderly person 
In addition to that, the public health system or social health insurance schemes 
provide medicines free for charge for particular conditions such as: 
1. All diseases in the essential medicines list  
2. Any non-communicable diseases 
3. Malaria 
4. Tuberculosis 
                                                          
4
 The minimum currency value in the Iraqi market in 2015  is 250 ID≈ 1.6 NOK/January.2015 
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5. Sexually transmitted diseases 
6. HIV/AIDS 
7. Expanded program on immunization vaccines for children 
8.  Any other health problem(WHO, 2011). 
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2 Purpose 
 
The objective of this study is to describe the Iraqi price and payment system for 
pharmaceuticals and to explore the potential feasibility of the Nordic pricing and 
reimbursement model for Iraq, as perceived by pharmacists working in the Iraqi 
health care sector, focusing on Norway as a case.  
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3 Methods and materials 
In this section the methods and the planning will be described, e.g. the choice of the 
method and informants, the drafting, the interview guide and the data analysis will be 
explained.  
 
A qualitative research approach inspired by both  Malterud and Kvale/Birkeman was 
applied in the study, both explained that the aim of the study decides the method of 
the research(Malterud, 2011). Since the aim of the study concerns  the meanings of 
unexplored attitudes, a qualitative method is the best choice (Larsen, 2007). 
 
In this study, a multiple methodology approach was used to understand what ,why 
and how things work (Almarsdóttir & Traulsen, 2009).Three approaches were used;  
a review of the literature, qualitative interviews (since literature search revealed 
meagre data on pharmacists’ experiences/opinions and the general lack of 
information of pharmaceutical pricing system as a whole in Iraq), and data collection 
of diabetes in Iraq/Norway as a case to exemplify differences in availability and 
affordability of medications. 
 
3.1 Literature review  
Literature was obtained both from published research reports, newspaper articles, 
books, as well as from the internet pages of various authorities and organizations. 
Several international researchers have provided the study with charts by private e-
mail. The literature search was done in Google, Google scholar, PubMed and the 
electronic library for the University of Oslo. The searching key words were around: 
Nordics, Iraq, Kurdistan, Pharmaceuticals, reimbursement, pharmaceuticals pricing, 
EU health care system, and feasibility studies, pharmaceuticals companies in 
Kurdistan, pharmaceutical system, Nordic pharmaceutical model and Iraqi crisis. 
These words resulted in more than 1000 articles.  
 
The literature search for the pharmaceutical system in Iraq gave limited results. For 
example, there were few articles about pharmaceutical pricing and policy in Iraq. No 
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feasibility of foreign pharmaceutical pricing and reimbursement systems studies for 
Iraq were found. The Nordic literature search was rich. Generally, the literature 
search strategy was developed by means of internet and personal views. The data 
about the pharmaceuticals reimbursement and pricing system for Nordic countries 
were collected from the published research reports, articles, journals as well as the 
internet pages from some authorities. All articles were collected between 01.04.2014 
and 30.12.2014. 
3.2 Qualitative interviews  
Semi-structured interviews were used to get answers to the questions, with this 
method the interviewee can give broader information than with other methods like the 
questionnaires (S Kvale, 2009; Steinar Kvale & Brinkmann, 2014). 
3.2.1 Thematization 
This phase include the development of the topic guide questions according to the aim 
of the study(S Kvale, 2009; Malterud, 2011). An interview guide consisting of eight 
open ended questions was developed (see Appendix 3), by aiming at mapping and 
understanding the Iraqi pricing model in different geographic areas (North-Middle and 
South of Iraq) and to shed light on the aim of the project from the pharmacists point 
of view, to explore the potential feasibility of the Nordic pricing and reimbursement 
model for pharmaceuticals in Iraq. 
3.2.2 Choice of data collection method 
The design was a semi-structured in-depth interviewing via Skype and/or face-to-face 
to map the experiences and views of pharmacists. The use of this type interview can 
help to get broader and deeper answer from the interviewee, follow up better by the 
interviewer, and ensure the right understanding to the questions. All the interviews 
were concentrated in the same aim with the possibility of supplement questions if 
they were emerged for other interesting topics. The interview topic guide started with 
indirect questions and the purpose will be explained at the end of the interview by 
using the funnel technique, a good interview questions should be thematic and it 
should be dynamic to create a good interaction in the interview(S Kvale, 2009). 
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3.2.3 Informant choice and recruiting  
The project plans to recruit for qualitative interviews and the inclusion criteria were 
the pharmacists from Iraq and Nordic countries, that have diverse mix of knowledge 
from different pharmaceutical sectors and from different geographic regions in Iraq 
(North, South and Middle); such as pharmacy leaders, wholesalers owners, a 
decision maker such as the manager of pharmacy department in MoH and 
academics and lecturers, a mix of both genders. The method of recruiting informants 
was through own network, partly through snowballing. In addition, a colleague’s 
network, such as LinkedIn and FIP (International Pharmaceutical Federation), was 
used to recruit informants. 
 
The researcher did not have an opportunity to travel to Iraq. Hence Skype-
interviewing was used.  
 
Initially 20 individuals from Norway, Denmark, Sweden and Iraq, with 10 to 35 years 
job experience were invited to participate, but only eleven wanted to participate. 
Invitation letters were sent to nine pharmacists with  Iraqi background, but working in 
the Nordic countries (Sweden, Norway and Denmark) but just two of them wanted to 
participate, two answered with no, four didn’t respond and one accepted but later 
pulled back. On the other side, eleven Iraqi pharmacists living in Iraq (or temporarily 
studying abroad) were invited to participate. Nine of them accepted, and two did not 
respond.  
 
The only reason given by a participant for turning down the invitation to be 
interviewed was the political situation in Iraq especially in this period (Iraqi crisis 
period), the weak confidence and the skeptical/ difficult situation of most of them as 
they had political refugee backgrounds. Otherwise, the pharmacists were busy and 
had no time to participate and some may have been skeptical towards this contact 
from an unknown person. Recruited informants were informed about the purpose of 
the study via a formal invitation letter (see appendix 2), information attachment (see 
appendix X7) and consent for participation (see appendix 2).The aim was to recruit 
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informants until data was saturated. The last two interviews in December 2014 with 
two informants from Iraq gave the same results and no change in the results 
occurred. Therefore, the data seems to be saturated. The interviews were conducted 
in the period between 23.05.2014 and 26.12.2014. 
3.2.4 The interviews  
The one-to-one interviews took place through Skype / face-to-face interviews in 
Norway. The duration of the interviews was between 40-60 minutes. Skype 
interviews took place with video on while interviewing, but only audio recording. The 
main interviews took place in the period between the end of May 2014 and the 
beginning of December in 2014. 
 
The first interview with the first informant was used to test the interview topic guide as 
a pilot interview. The pilot interview was done with a pharmacist from Iraq who was a 
pharmacy owner and also a PhD student in a university in USA. This interview was 
not used in the results but it is used to reflect on the interview topic guide. Unclear 
questions were identified and adapted better to the interview with the first informant. 
  
The study informants received formal invitation letters informing about anonymity and 
confidentiality issues of the study and about the use of Skype being secure according 
to Skype legal privacy policy (see Appendix2). The Skype-account for interviewing 
was deleted after data-collection. The researcher also explained that the participation 
in the study depended on the consent of the informant, and consent for participation 
was obtained verbally by telephone or in writing by e-mail. The interview conversation 
was relatively spontaneous.  
 
At the beginning of the interview, before turning on the recording, a few issues of 
information and clarification were mentioned:  
1. It was explained that the interview could be muffled and there might be 
unexpected cut-offs and interruptions. If this would happens, the researcher would 
make a new attempt to get through. 
2. The pharmaceutical pricing and reimbursement system in the Nordic countries was 
briefly explained. 
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3. It was explained that the informant could choose between; Arabic, English or 
Norwegian. 
4-It was explained that the dialogue would be free flowing 
It was explained that the informant would be anonymous in all published writing 
about the project. 
 
The study was approved by the NSD (Data Protection Official for Research); (see the 
notification form in appendix 6).The informant’s sensitive information was 
anonymous. According to NSD, the notification of the study is compulsory when the 
researcher uses computer based equipment like text, audio or video. 
3.2.5 Transcription  
Interviews were tape recorded and transcribed at the same day of the interview. The 
questions were written in English, but the interviews were performed in Arabic. Each 
interview was heard many times to ensure that everything had been understood 
correctly and they were no missing words (see appendix 4). Interviews were 
transcribed in Arabic and translated into English. The method for translating was by 
using the Word 2010 translator, combined with the researcher’s understanding of 
Arabic, which is her native language. The translation was done paragraph by 
paragraph to get the most accurate meaning. 
 
 The Skype account was erased after use and the tapes will be erased on the 
completion of the study. All personal identifiers have been removed from quotations 
in this thesis and from the transcripts. 
 
3.2.6 Analysis  
The purpose of the analysis phase of the interviews is to produce information about 
attitudes and values. According to the inspiration of Kvale and Malterud , an 
approach similar to Malterud’s meanings condensation method used in the analysis 
of the interviews(S Kvale, 2009; Malterud, 2011).The meaning condensation method 
can illuminate the meanings bearing units (words) from the informants response and 
answer and amend them for shorter sentences and codes (Malterud, 2011). Key 
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words in the coding process were pricing, margins, reimbursement, feasibility, 
benefits, availability and affordability. 
 
The analysis of interviews process took five steps. The first step was through the 
reading of the transcribed interview in order to make an overall impression and 
without having the theme and the aim of the study in mind. The second step was to 
read each interview again but taking in consideration the informant´s attitudes and 
values. The third step was to reformulate the relevant units of opinions in short 
sentences and divided into items, and the information related to the aim of the project 
must be in focus. The last two steps were  to make questions to choose the 
information related to the objective and write them in descriptive text of each theme, 
as presented in the section of the results (Malterud, 2011). 
 
The analysis initially was  done manually, thereafter transferred to hyper research 
program to get a better overview in the computer (Hesse-Biber, Dupuis, & Kinder, 
1991; Kinder, 2008). The quotations in the results chapter were interpreted and 
written in the researcher´s words only the best quotations were used in the text (S 
Kvale, 2009). 
3.2.7 Validity, reliability, and generalizability 
 
This include the evaluation of the terms; validity, reliability and generalizability. The 
validity explain if the method chosen can illuminate the problem  and all the seven 
phases in the interview method decided the validity of the method. Reliability involves 
whether one can trust the results of the study. This is often related to the survey 
results can be reproduced by other researchers using the same method. The 
generalizability related to whether the results of the study can be transferred to other 
informants and other situations (Malterud, 2011). However, the study cannot 
generalize globally, but it can be generalized compared to similar situations in the 
world, that is countries that have similar conditions to the Iraqi conditions. 
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3.3 Diabetes case  
In addition to the literature review and the qualitative interviews, a case study was 
applied on the diabetes treatment in Norway and Iraq. The case focused on 
differences in availability and affordability of medications in Norway and Iraq to 
illustrate differences in pricing and reimbursement models for diabetes medications. 
Data was collected on pricing and margins information. This included some 
unpublished data from MOH institutions in Iraq. About diabetes treatment from 
different sectors and areas and from the institutions (see Appendix 5).  
 
A data collection form (see appendix 5) was developed to address the available 
medicines in diabetes treatment in Iraq and Norway in order to collect information 
about pharmaceuticals and blood sugar measurement devices access in Iraq, and to 
get clear idea about the difference in treatment options in Iraq versus Norway. 
  
The table was sent to some of the project informants after a deal with them and 
asked them to collect the sample in two different areas in Iraq, one in North Iraq 
(Kurdistan) and the other in South Iraq. In addition to the table, the informant collects 
some pictures to show some of diabetes treatment forms and measurement 
instrument, and this available in Iraq from one of the Diabetes clinics, its pharmacy 
store and a private wholesale store. 
 
 The Diabetes table has been analyzed with simple calculations by the researcher, to 
compare the prices after reimbursement in Iraq and discuss the expectancy of 
reimbursement price in case of reimbursements application in public and private 
sector. This will be illustrated later in the text. In addition pictures demonstrating 
availability are shown in the result section. 
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4 Results 
4.1 Overview of the result section 
The figure below summarizes the results of the study depending on the analysis of 
interviews and gives an overview of the following result section. The main sections 
are: A) Reimbursement, pricing and margins; B) Feasibility of the Nordic system for 
Iraq and C) Affordability and availability of medications. Under each main section 
several sub-sections follow for further exploring the study aim (see Figure 7).  
 
 
Figure 7. Overview of the results chapter related to the pharmaceutical Nordic 
pricing and reimbursement system.  
 
 
 
 
The results of the qualitative interview and informant recruiting are shown in details in 
the table below (see table 4). The duration of the interviews was between 40-60 
minutes. The result of the coding process was 22 codes based on the informant’s 
interviews and the aim of the study (table 5).  
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Table 4. The characteristics of the informants.  
Feature Number 
Male / Female 8 / 3 
Iraq / Norway 9 / 2 
North Iraq (Kurdistan)/ South / Middle / Norway 2 / 3 / 4 / 2 
Pharmacy owner / Employer  9 / 2 
_Civil servant * 5 
_Scientific bureau*   2 
_Academic pharmacist* 4 
_Whole sale owners* 2 
*Duplication in job area 
 
Table 5. Codes resulting from the data analysis of interviews, 3 main categories 
and 19 subcategories. 
A) Reimbursement, Pricing, Margins  
• Pricing decision of pharmaceuticals in public sector in Iraq. 
• Pricing in public sector. 
• Pricing of new pharmaceutical. 
• Margins in public sector. 
• Pricing in private sector. 
• Factors affecting on pricing in private sector. 
• Margins in private sector. 
• Reimbursement similar arrangement in Iraq. 
• Definition of semiprivate clinics. 
• Pricing in semiprivate clinics. 
• Mechanism of pricing in semi-private clinics. 
• Margins in semi-private pharmacy. 
 
B) Feasibility of Nordic pharmaceutical system in Iraq 
 
• Advantage and Disadvantage of now a day’s pharmaceutical system in Iraq. 
• System Development trails in Iraq. 
• Advantages and Disadvantage of semiprivate pharmacies. 
• Barriers and problems to apply Nordic system in Iraq. 
• Changing possibility in future/method to change. 
• Reaction of different actors to reimbursement idea. 
 
C) Affordability and availability of medication in Iraq 
 
• Diabetes case 
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4.2 Pricing and margins system of pharmaceuticals 
in Iraq and a reimbursement similar system (public 
and private sector) 
Firstly, the pricing in the public sector will be described followed by the private sector. 
Then and according to the informants, the pharmaceutical system in Iraq could be 
summarized by this flowchart below which show the procurement of pharmaceuticals 
and the decision makers in pharmaceutical system as a whole both public and private 
sector (see figure 8). The figure below developed by the basis of the information from 
informants and some online research on some national health authorities in Iraq. 
 
Figure 8. Flow chart of the pharmaceutical system in Iraq.   
 
 
  
a) Syndicate of Iraqi pharmacists (SIP). SIP  was founded in 1967 after it was legislation Pharmacists Syndicate Law No. 
112 of 1966 to be an independent institution for the union health professionals caring affairs profession of pharmacy and 
pharmacists in Iraq and is working to achieve the goals contained in the law and seek the union to contribute to 
improving the health status of the construction of the human through practice scientifically valid and legal profession of 
pharmacy check with the rest of the health professions building a sound health system is headed by the current union, 
Dr. Mahmoud Abdel Rasoul Louis  
[X] The control committee consisting of representatives from MoH, Pharmacists syndicate and the local DoH is 
responsible for approval and laws, it’s has the same role of medicine agency in some European countries, directorate of 
health responsible for authorization. This control process is just for private sector to control the professional laws. 
b) Domestic manufacture Local Iraqi private pharmaceuticals production which with authorization from MOH according to 
GPM(Good Manufacture practice ) Domestic manufacture have small and pharmaceuticals with no specialist products 
.Very small part of private sector . 
c) KIMADIA has the procurement’s responsibility in public sector 
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According to the informants and the scant literature available, the pricing of 
pharmaceuticals in Iraq in the private sector is different from the public sector. The 
procurement of pharmaceutical process in Iraq in public sector has been described 
by many informants and be illustrated with figure above (figure 8). 
 
Informants mentioned that there is a committee of drug selection at the Ministry of 
health that has the responsibility of selecting which type of medications can enter to 
Iraq for both public and private sectors in the pharmacy department in the Ministry of 
health. The national drug list which can be sold both in the private sector and the 
public sector and the essential drug list which is restricted to the public sector only 
and there are the lifesaving drugs only. 
 
Every governorate has a nominated center DoH, public sector institution, where 
requirements of pharmaceuticals for the following year for that governorate have 
been collected, coordinated and collated and a single report and submission 
prepared. Then the information is sent to Baghdad MOH to the Technical department 
who studies and evaluates the submission, looking for example for requests for 
obsolete pharmaceuticals and potential to substitute newer or more efficacious 
treatment. 
 
Different committees have been involved in this process and a list for 
pharmaceuticals is prepared and sent to Department of centralized Needs where 
quantitative elements of requirements are prepared A statistical study is done on the 
background of known factors e.g. population, diseases prevalence.  This includes a 
discount factor applied on the basis that is believed each health district over 
estimation of its requirements for the forthcoming year. In practice, this is just an 
estimation numbers and lists. 
  
The specialist hospitals and clinics submit their own requirements, which are then 
evaluated separately. The evaluation of the lists might be according to domestic 
availability, quantity against availability, quality of imports (versus domestic 
production) and price. Tenders are then issued by KIMADIA. 
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4.2.1 Public sector: pricing system and pricing of new 
pharmaceuticals  
All informants mentioned that in the public sector, the decision maker to 
pharmaceuticals procurement is from the MOH. That means that the government   
has the responsibility to buy the pharmaceuticals and to distribute it free to the 
patients or public sectors users. KIMADIA is supported by state budget. The state 
pays to the pharmaceuticals companies by KIMADIA and the patients get free 
medications -100% “free”- in public sectors for both inpatients and outpatients in most 
parts of Iraq. Some of the informants mentioned that the patients pay just a minor fee 
to the public institutions to get a ticket between (1-5 $ =7-35 NOK in December 
2014).5 Some informants expressed that by “In the public sector the medications are free 
and the patient will pay from 1 to 5 dollars to get a ticket but the medications are free for both 
inpatient and outpatients” (Informant No.6) 
 
According to the informants, the ticket simple value taken by the Finance minister 
and the purpose of the ticket is to support the registration process at the institutions. 
It could help in some simple reparations in the building of institutions as example; but 
it is not so big income. The public sector is just consumer in its budget and there are  
no co-payments by patients. It is the state government budget only that supports the 
procurement process from the oil fund budget. There are no taxes funds 
recommended to support the health care system as a whole. The pharmaceuticals 
procurement cost the state millions dollars (about 5%6 of the government budget) to 
support the health care system, as well the pharmaceuticals procurement and other 
health services.  
 
Many informants thought that the public sector now was not a correct system 
because the state will consume all the resources to buy some essential 
pharmaceuticals. This may lead to limitation in the availability of the expensive 
pharmaceuticals because of the deficiency in the money (The budget). A couple of 
informants expressed this, one said “ I think the pricing system now is not correct, 
especially in the public sector because the state will consume all the resources to buy the 
medications over the real need to the user” (Informant   No.11) 
                                                          
5
  USA 1 $ = 1178 ID( Iraqi Dinar ) = 1000 ID = 5 NOK (the next minimum market value in Iraq today 
6
 According to (the literature research from) the WHO website  
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4.2.2 Public sector: pricing regulation Mechanisms  
According to the informants, the pricing regulation mechanism in public sector is 
approximately the same in Kurdistan area and the rest of the Iraqi regions (South, 
Middle and west). Iraq MOH and Kurdistan KMCA apply the same principle in 
procurement policy. The pricing decision in public Sector depending on professionals 
decision makers. The informants further described that there are committees in the 
MOH and KMCA, including the department of pharmacy. The Pharmaceutical 
purchases committee consists of pharmacists, economists and physicians. The 
committee does not use an economic health economics analysis. There is no 
effective use to the cost utility analysis. They only include economic view of the 
decided yearly budget. One informant from MOH Baghdad emphasized that: 
“Generally there is no organized economic evaluation”. (Informant No. 4). 
 
Generally, the mechanism in pricing depends on the procurement/Purchases 
committee) which is a part of the MOH. The committee is responsible for the 
selection of pharmaceuticals that enter Iraq in both private and public sectors. The 
MOH establish this type of committee to include many opinions in the annual 
pharmaceuticals’ need decision .The economic role in this committee is to connect 
the MOH with Finance minister to get information about the financing ability of the 
state and on, how much the state has budgeted for the health care sector 
 
An informant (a decision maker 7of pricing with pharmaceuticals), mentioned the 
mechanism of the pharmaceuticals in public sector and the process of purchases and 
the responsibility of MOH to buy the medications for the patient in Iraq and how the 
state pay to the pharmaceutical companies to provide free medications to Iraqi 
patients in public sectors, saying: “KIMADIA is responsible to buy the medications. It is 
supported by state budget given to MoH. The MoH budget depending on the budget from the 
Oil fund 95%, less than 2% from taxes. All the medications must be registered and have 
quality control permission before the pricing of pharmaceuticals.” (Informant No. 1) 
 
The informants’ descriptions of the pricing mechanism in Iraq and Kurdistan were 
similar. This was expressed  in the words of one of the informants :-“The pricing 
                                                          
7
 Chairman, a part of Ministry of Health  
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mechanism depending on the registration price and the previous import price of medications 
(The previous import contract price) This is an evaluated or estimated price not standard for 
example insulin import price in 2013 from Novartis was 10 dollar per Vial in import contract 
for 2013 with the import company, to write a new contract for 2014 for the same product re-
evaluation happened, after negotiation and agreement on purchases price from the 
manufacturer.” (Informant No.1) 
 
The figure below (see figure 9) shows the mechanism of the pricing and procurement 
process and the different actors who are responsible on the pharmaceutical 
purchases in public sector both in Iraq and Kurdistan regions, similar pathways 
noted, according to all informants.  
 
Figure 9. Pricing process in Public sector in Iraq and Kurdistan. 
 
 
 
 
 
The pricing of pharmaceuticals procurement’s decision depend completely on the 
negotiation between the state and pharmaceuticals companies. There are many 
factors, which affect the price of new pharmaceuticals in the Iraqi market and its 
procurement price. The registration department in MOH calculates the pricing of the 
new medications in Iraq and gives it registration documents, and then it will be sent to 
a) KIMADIA=The State Company For Marketing Drugs and Medical Appliances which is the only IRAQI company which  is 
specialized with regard to importing ,storage and distributing of pharmaceuticals and Medical appliances and Equipment’s 
regarding the public sector institutions in Iraq and Kurdistan ,involving (General hospitals, popular clinics and public health 
centers ) KIMADIA was established in 1964.   
b) KMCA= Kurdistan Medical Control Agency   
[*] See figure 10 
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the committee for the purchases of medications. When the committee agree with the 
pharmaceutical company and decide the purchases price, then a procurement order 
send to KIMADIA, which has funds from the oil budget to buy the pharmaceuticals 
and distribute it to the public institutions only. 
 
In addition to that and according to many informants, usually the hospitals can get a 
special budget from the state’s oil fond to buy the remaining of the pharmaceuticals 
they need from the private wholesalers, especially in the last years because of the 
lack in availability and the wrong pharmaceuticals needs estimation. The final 
consumers of pharmaceutical get it “100% free” of charge in public institutions (public 
hospitals, health care clinics and public clinics).The last two informants of the study in 
December confirmed the availability problems in public hospitals and the mechanism 
of hospital purchases. One of them expressed that by saying: "Not all the 
pharmaceuticals available in public sector hospitals, about 70% available now and the rest 
can buy by the hospital budget" (Informants No.10). For more details see figure 9 above 
and figure 10 below. 
 
Registration price is important also for the process of pricing for pharmaceuticals in 
Iraq. According to informants from the Ministry of health/department of pharmacy; the 
registration price for the neighboring countries Jordan, Kuwait, Turkey, Saudi Arabia 
depending on the similarity on the environmental conditions and the stability study for 
different pharmaceuticals. “It is priced speculative by using the Ex-factory + 55% which 
represent the tax, shipping and transportation and other expenses. We take the lowest price in 
neighboring countries” (Informant No.1). The procurement price in principle is 
estimated according to this simple calculation sentence: 
 
“X- Factory price + 55% of the price (for taxes, transport and other shipment cost). 
 
This was process of pricing in the public sector. The same informant underlined that 
“The state pay to the pharmaceutical company and the patient get free medications” 
(Informant No.4) 
The registration price and the origin of it is demonstrated in procurement process in 
public sector in figure 9  and the factors which affect this price will be demonstrated in 
figure 10 below.  
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Figure 10.Factors influencing the registration price and procurement of 
pharmaceuticals in public sector in Iraq. 
 
 
 
 
 
 
 
The public sector pricing mechanism in Kurdistan, the northern part of Iraq is 
depending on the central MOH and KIMADIA policy in pharmaceutical purchases and 
budget from the central government in Baghdad (MOH). Due to slight differences 
between Kurdistan and the rest of Iraq, pricing and reimbursement for Kurdistan will 
be addressed specifically in the following, for example in sections 4.2.5 and 4.3.3. 
4.2.3 Public sector: margins  
Generally all the informants agreed that there are no co-payment from patients and 
the pharmaceuticals are 100% reimbursed by the state no margins in public sector 
institutions. The patients get medications free which is originally funded by the oil and 
the state. The pharmaceutical companies only get the money and margins from the 
state according to price negotiation. The informants generally thought that the 
a) BP: The British Pharmacopoeia the official source of British pharmaceutical standards. The 
reference price according to the British Pharmacopeia in case of application of new 
pharmaceuticals, in Iraq they used to use the British pharmacopeia as a reference in both 
formulary and Prices the previous price is the previous import contract price. This is an 
evaluated or estimated price not standard for example; insulin import price in 2013 from 
Novartis is 10 dollar per Vial in import contract for 2013 with the import company then to write 
a new contract for 2014 for the same product re-evaluation to the price happened. Some 
informants emphasized that.  
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pharmaceutical companies were the winners having the highest margin in both 
sectors (public and private sectors). 
4.2.4 Private sector in Iraq and Kurdistan: Pricing and margins 
regulation  
From the informant ‘point of view, there were variations and multiple 
sources for entering of pharmaceuticals in private sector: external suppliers 
that supply new products in the control of MOH /KIMADIA); importers and distributors 
(private scientific bureau); low cost manufacturers and high value manufacturers 
(capital cost currently small domestics market) 
 
According to the informants, there is no organized pricing system in the private sector 
for pharmaceuticals and no fixed prices. For example, generally speaking, the pricing 
for pharmaceuticals differs from pharmacy to pharmacy depending on many factors 
such as the location of the pharmacy, rent, employers, transport and other factors. 
The informants gave different impressions about the pricing system and described 
different aspects in the private sector, from their private practice as a pharmacy 
owner, wholesale owner, and scientific bureau owner from different regions in Iraq. 
 
There is a significant difference in pricing system and the margin level between Iraq 
and Kurdistan as regards the private sector and community pharmacies. The figure 
below (see figure 11) shows the pharmaceutical procurement in the private sector in 
addition to the pharmaceutical margins in the private retail pharmacy in Iraq. The 
pharmacy final price is the patient’s price. The margin presented is per package. 
Informants pointed out, that there is no reimbursement/third part payment for patients 
in the private pharmacies, because it was just a private business to every pharmacist 
and pharmacy owner; and the patient have no economic support from the state when 
the patient buys a medication from the pharmacy. An informant said that; “There is no 
chain pharmacy, each pharmacist has his own independent pharmacy, the patient must pay 
cash total fee for prescription, the patient must pay on time or not get the medication". 
(Informant No. 3) 
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One informant explained of his experiment that the price of medications in the private 
sector in Iraq is divided in two pricing level according to the source of production, 1st 
level, the expensive one come from Europa and America, the 2nd level of medications 
pricing from the private sector, the cheap level of pricing are medications which are 
produced locally or coming from Asian origin. «The patient must pay by himself for 
medications, anyhow, if he can”! (Informant No.6) 
 
 Figure 11. Flowchart for pricing and margins of pharmaceuticals in private 
sector in Iraq in 2014. 
 
 
 
 
 
On the variation in pricing between the different pharmacies, one informant from Iraq 
described causes of this variation by mentioning many factors which could affect the 
price of every pharmacy in Iraq “There is no pricing model in Iraq for the private sector, every 
pharmacist sell medications with the price which he/she thinks is good depending on the pharmacy 
locations, wholesale price and other factors such as local rent, staff, paychecks, electricity, transport 
and other bills”(Informant No.4). 
 
a) Definition of scientific bureau (SB): an importers office is acting as agents or 
representatives of oversea manufacturers or manufacturer agents. They make their 
purchases either directly to the wholesalers and to the retail pharmacist or to the private 
health care institutions. 
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 Sometimes, the pricing depends on the commercial competitions between 
pharmacies, the informant mentioned that by: “The pricing each pharmacy is usually 
depending on the demined and the supply and competition between pharmacies at the same 
area” (Informant No.8).  
 
Generally speaking, all the informants agreed that the retail price in community 
pharmacy depends on the original price from the Import Company, Scientific bureau 
and wholesalers. As regards that, an informant who has a scientific bureau in 
Baghdad expressed: “The import company + scientific bureau are the decision makers to 
pricing in private sector in addition to the wholesale and pharmacy who decided the final 
price to the patient” (Informant No.5). 
 
The pricing in the private sector and pharmacy margins are different in Kurdistan, 
there are no scientific bureaus there, but they have agents for the brand 
pharmaceutical companies. There are about 50 brand agents and there are more 
than 200 direct generic companies, according to informants from Kurdistan. There is 
a direct pharmaceutical market and more open market in the private sector with high 
margins percentages. 
 
Generally, there is a pricing policy8 in Kurdistan exists more pharmaceutical control 
by the KMCA (Kurdistan Medication Control Agency) and the Pharmacy Syndicate. 
The pricing system and margins determination in Kurdistan is mostly responsibility of 
pharmacy syndicate in cooperation with KMCA. According to an informant from 
Kurdistan, the pharmaceutical companies add 100%-200% margins for their 
products, sometimes the prices of the companies are higher in Kurdistan than in 
Turkish market from the same patent company." we have the original pharmaceutical 
companies managers in Kurdistan. The method of manufacturer pricing for them is unknown, 
but the margins for them is between 100-200% especially in Kurdistan in compared with their 
market in Turkey “(Informant No.6). The pharmaceutical pricing process in Kurdistan is 
demonstrated by figure 12 below: 
 
                                                          
8
The pricing policy by which a company determines the wholesale and retail prices for its products or services 
(this is a general definition to pricing policy, the study about the pharmaceuticals and its pricing strategy in 
Iraq. 
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Figure 12. Flowchart for pricing and margins of Pharmaceuticals in private 
sector in Kurdistan in 2014.   
 
 
 
 
 
 
A couple of informants from Kurdistan expressed that there was a start of new 
pharmaceutical pricing policy and pharmaceutical control strategy. The labeling of 
package with retail price noticed in Kurdistan only. One informant described this by 
saying: “Now, there is a committee for pricing and there is a pricing label model which 
shows the retail price in Iraqi Dinar in the label documented from Kurdistan medical control 
agency“ (Informant No.9).There is a label to indicate the quality control sign in 
Kurdistan from KMCA. 
 
The figure 13 below shows the stamp of Medical Control Agency and the central 
pricing from the Ministry of Health in Kurdistan. However, this price in the label is not 
a 100% mandatory in different community pharmacies. Sometimes it will be a plus or 
a minus depending on other conditions to the pharmacies, e.g. location, employee 
and other bills. An informant from Kurdistan mentioned that there are efforts in 
Kurdistan to get maximum price system in but it is just a trail in KMCA “It is just six 
a) Margins decision depends on competitions with each other and negotiations with 
wholesales. 
b) Margins decision depending on competition. 
c) Limited margins decided by KMOH (Kurdistan Ministry of Health) 
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months old and now it is illegal to sell medications without this label, but not in other parts in 
Iraq” (Informant No.3)  
 
Figure 13. Pricing policy in Kurdistan (Pricing label model example). 
 Paracetamol tablet   
 
 
 
 
 
 
Another informant from Kurdistan mentioned that there was a change in pricing policy 
in the period 2012-2013, but it stopped. «The new pricing policy stopped in 2014 because 
of many problems for this system. The most important one is the increasing in medications 
prices to 20-30%. So it stopped in 2014” (Informant No.6). 
 
Many informants emphasized that there was a start for a new pricing system in 
Kurdistan, but now in 2014 it stopped because of many problems such as the sudden 
increase in pricing. They said that there was a pricing scheme in Kurdistan, but it did 
not succeed and stopped in 2014 and the dramatically increase in retail price for the 
pharmaceuticals was the reason to stop it.  
 
Informants from Kurdistan explained that this scheme was decided by the pricing 
committee KMCA in Kurdistan by making a contract with the mother company and 
made negotiations depending on the mean of prices for the same medication in the 
neighbor countries (Jordan, Kuwait, Turkey, Iran and Saudi-Arabia). One informant 
a)FDAS Britt No: FDAS,a British company that according to their website ,signed an «agreement 
with Kurdistan Regional Government in September 2012 to provide (analytical testing services to the 
Kurdistan Medicines Control Agency (KMCA) to support actions to improve the quality of 
pharmaceuticals in Kurdistan region of Iraq. Photo: Food and Drug Analytical Services Limited (web 
sides) 
b) Valuate exchange in 01.12.2014 
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explained that “They divide the medication price to 6 levels to decide the price and get the 
margins”. (Informant No.6)  
 
The informant described these levels as; 
The first level: in which pharmaceuticals with less than 1 dollar the permitted 
margins is not more than 30-35% in pharmacy and 50% margin to the company; 
The second level: if the pharmaceutical price is between 1 and10 $ the permitted 
margins is 30% to the pharmacy and 50% margin to the company; 
The third level: when the pharmaceutical price between 50 - 100 $ the permitted 
margins is just 5% to the pharmacy and 10% to the company and so on. 
 
It was a good start but the “dirty job9” and the commercial swindle of some 
pharmaceutical companies and wholesalers; the retail price of pharmaceuticals, 
increased dramatically in Kurdistan to 20-30%, therefore the system stopped.  
 
The informants generally thought that there is a type of flexibility of margins in Iraq, 
and the margins of pharmacist in community pharmacy now coming from: 
 
 «Wholesale price + location + competition between pharmacies + employee’s paychecks». 
  
All these factors must be taken in consideration to calculate the final price to the 
patient and the pharmacist’s margins. 
 
In addition to all this, some pharmacies can get higher margins than others, because 
of the pharmaceutical agents from the pharmaceutical companies. They can give a 
direct offer to the pharmacist so there is no intermediary (middleman), no wholesaler 
so the medication will be cheaper, - then the price can be lower in some pharmacies 
or the margins can be larger in some pharmacy, so it depends on the pharmacy 
owner’s decisions itself.  
 
On the other side, informants from Baghdad and other parts of Iraq (middle, west and 
south Iraq, not in Kurdistan), have got a new system to regulate the margins in 
                                                          
9
 Se definition of dirty job in Glossary section! 
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private pharmacy. This was applied after an agreement between the registration 
department in MOH and the pharmacy syndicate in Iraq to estimate a method for 
margins. An informant exemplified this type of system (trail)by: “If the company price 
of X-Drug is 10 dollar so the margins of the wholesale must be not more than 10% 
and the pharmacy margins cannot be more than 15-25% depending on the original 
price of medication if it is expensive medicine, the margin will be minimum in 
Pharmacies” (Informant No.1). Another informant mentioned that the margins in Iraq 
could be not more than 40%. «The pharmacist himself decides his margins to get about 
40% margins» (Informant No.4). 
 
The informants generally thought that  the margins of the pharmacist in private 
pharmacy in Kurdistan were higher than in Iraq; and this was described clearly by 
one of the Kurdistan informants who said: “the minimum margins of pharmaceutical in 
retail price in Kurdistan is 30-35% ,and sometimes have 100-200% margins. The 
prices of medications are lower in Baghdad” (Informant No.3) 
4.2.5 Public and private sector: a divided “reimbursement” system  
 Some informants described this system in one sentence: “It is a type of a 100% 
Payment free system” while others informants described it as «a semi-socialist 
system». Two informants from KMCA emphasized that there has been a 
development in the pharmaceutical system in the public sector in Kurdistan regarding 
a new experiment in reimbursement to get medications and good health service. In 
this new system which is restricted nowadays in some of the Kurdistan areas such as 
Erbil, Sulaimania, Dohok, and Holier. 10 There is a beginning plan of mixing the 
private sector with public to get better service to Kurdish patients. One informant 
described “The government pays to the private pharmacy, to the pharmacist, 50% of 
the total price of the prescriptions per month” (Informant No.6). 
 
The margins for a pharmacy in this type of clinics are restricted to just 12% of the 
pharmaceutical price. These pharmacies are just in a special type of a public clinic, 
which is known as a consulting clinic. The pharmacy there is called a semiprivate 
pharmacy because it is managed completely by the government and partially 
                                                          
10
 Big cities in Kurdistan region 
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financed by the government. These clinics give good health care services. It is an 
optional job for the pharmacist to work in. It has good benefit and help to the poor 
people to increase the affordability of medications. An informant expressed this: «For 
example: if the purchases for pharmacies is 100 million Iraqi dinar per month, the margins 
for this pharmacy cannot be more than 12% for the pharmacist and 50 million dinar pays to 
the pharmacy from this clinic as a co-payment from the state (Clinic)”(Informant no.9) 
 
According to the informants, the characteristics of these clinics are a special opening 
time between 2 o’clock to 6 o’clock and there were about 10 clinics in Kurdistan with 
contract between the clinic and the government, moreover it is a contract that 
contains more than 20 terms to secure the re-payment to the pharmacist and other 
clinic services. This clinic contains specialists, laboratories and other types of health 
services, all services charges in these clinics would be reimbursed by the 
government. This is the first sign of a start of co-payment and reimbursement but just 
in Kurdistan. 
4.3 Feasibility of the Nordic system for Iraq 
The informants generally thought that, the feasibility for applying any new system in 
Iraq depends on the development of the country and its political situation as a whole. 
Some of them thought that the system could be improved to something like in the 
stable countries, which have advanced technological control to avoid abuse.  
 
Some informants thought the possibility to change must start with fixed price and 
margins. In addition, they mentioned that the decision maker, pharmacy syndicate 
and the MOH might have the responsibility to apply. One informant mentioned that 
the establishing of the new system in Iraq needs to study patient behavior on the 
reimbursement, and the understanding of administrative structure to such types of 
systems in other models is not enough. 
 
Most informants thought that it would be a good idea if the governments made a 
good contract with the private pharmacies, and the government must have 
pharmaceutical policy makers with a good, professional view. Most informants 
thought that the change can happen, but it will take time and adaptation of the Nordic 
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pharmaceutical system to Iraqi conditions “to make it, maybe we need 10 years job, with 
gradual change in the existing pharmaceutical system” (Informant no.5). Many informants 
mentioned many barriers that are not easy to cross, especially due to the political 
situation. Two informants mentioned that it is possible and necessary to try it with a 
few pharmacies as a pilot pharmacy in Najaf, Karbala and Kurdistan. 
 
Some of the informants expressed that the acceptance of this idea could happen 
gradually. Informants mentioned that “trust”/confidence between different actors was 
needed; computerized systems and solid systems to ensure the re-payment process 
between the pharmacist, patient and government. Many informants thought that, 
firstly, there is a need to improve the cooperation between the public sector and the 
private sector. One of the informants views about that in  the future «I think if we can 
mix between the private and the public sector and make cooperation between them then it 
will be a good result to get good availability and more affordability”.(Informant no.1).  
 
The change has already started in pharmaceutical policies in Kurdistan; the 
informants mentioned that it would be a good system for the patients, especially for 
the expensive medications if the state reimbursed it. 
 
One informant from Norway thought that the change can happen in some states in 
Iraq but not all. The informant said" I think the changes can happen especially the 
reimbursement system in some of the states in Iraq in some private pharmacies  such as at 
Najaf, Karbala, Kurdistan because they are rich and can support the pharmaceutical’s 
budget, politically stable and safe, to be applied in one year with evaluation” (Informant 
no.8) 
4.3.1 Advantage and disadvantage of today’s pharmaceutical 
system in Iraq 
The informants gave an impression that the pricing system now is wrong and it could 
be difficult for many patients in the private sector and incorrect in the public sector 
because the state will consume all resources11some day and this can affect the 
availability of pharmaceuticals in the public sector. From the point of view of most 
                                                          
11
 The total health care  budget was restricted with 4,9 % of the total state budget in 2014 according to WHO 
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informants, that it seems to be beneficial to change the old system to the better in the 
future. They said that the only winner of this old system is the pharmaceuticals 
companies and some physicians. The patients partially benefits in public sector, but 
the problem is the availability and the table below (see table 6) will summarize the 
advantages and the disadvantages of the current pharmaceutical payment model 
and pricing system in Iraq. 
 
Table 6. Advantages and disadvantages of the existing pharmaceutical system 
in Iraq according to the informants.   
Advantages: Disadvantages: 
100% free for patients in public sector. No restriction in pricing and margins of 
pharmaceuticals in the private system. 
The pharmacists in the private sector always 
have a good margins level. (Minimum 35%) 
The government will consume all resources to 
buy the medications without partially contribution 
by the patients, could cause system abuse then 
leads to bad availabilities. 
The pharmaceutical companies, wholesalers, 
scientific bureaus have a good benefits and good 
margins (earn money). 
The patient cannot buy expensive medications in 
the private sector. 
 A profession lacks a scientific view because of 
the intruders a) in the pharmaceutical markets. 
 According to many informants, the corruption and 
the “dirty job” in public sector and the false 
pharmaceuticals in the private market are huge 
disadvantage.  
 
4.3.2 Attempts to develop the system 
Three of the informants mentioned some attempts to change the pharmaceutical 
policy in the last years. These are now described. 
4.3.3 Advantage and disadvantage of semi-private pharmacy 
a) According to an informant, the definition of an intruder is the owner of the capital who buys the 
pharmacist profession and the pharmaceuticals and non-pharmaceuticals and has complete 
capital to finance the community pharmacy. The pharmacist’s role in the community pharmacy, 
as an employer with a limited salary per month. 
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According to the informants; the first trial to implement a reimburse-like-system in the 
private sector for the pharmaceutical prices for the Iraqi patients in Kurdistan, were in 
the consultant clinics in parts of Kurdistan. The table below (see table 7) summarized 
the advantages and disadvantages of these type clinics in Kurdistan according to the 
informants. 
 
Table 7. Advantages and disadvantages of semi-private pharmacies according 
to informants. 
 
Advantages: Disadvantages: 
Most advantages to the patients who pay 50% 
of the total price of prescription and the state 
pay 50% to the pharmacist. 
Limitations in margins for the pharmacist. Only 
12% 
Good start for the contract system between the 
private pharmacist and the public sector (The 
government). 
The abuse of the system by the patient and the 
doctors because of the need and poorness. 
They could abuse todays “free” system as well. 
Patients can get pharmaceuticals at lower 
prices than in private pharmacies. 
Bad administrative control system to prevent 
the system misuse by the doctors and the 
patients. 
Low cost for all services to the patients 
because the government reimburses all the 
service. 
Economic problems to some pharmacists 
because of the confusion between the 
government and the pharmacists (Not 
completed re-payment to the pharmacist) 
Good quality of the health service with modern 
buildings, furniture, locations and good 
equipment. 
The patients misuse the actors in these clinics 
to get medications and sell it in the black 
market because of poorness. 
 The pharmacists do not have a complete 
guarantee to get his money back especially 
now with the Iraqi crisis.  
4.3.4 Reaction of different actors for the change 
The reaction of the different actors to the reimbursement idea from the informant’s 
point of view gave impression that the reimbursement of medication could be a good 
idea for the patients, but it is not easy for the government to create a completely new 
system and it is hard to apply from the government’s point of view. This idea needs 
trust between different actors and needs time to apply the new system instead of an 
old system. 
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One of the informants mentioned that the pharmacist would probably be dissatisfied, 
because of the limitations in the margin´s value decrease of their business. The 
doctors will not like the idea, because they could miss the benefit of the invisible 
income (dirty job income) related to the indirect deal with pharmaceutical companies 
and sometimes with pharmacies. An informants said about dirty job that” Illegal 
contract between the doctors and the pharmacy, not all but a lot..  There is a dirty job 
between the doctors and pharmaceuticals companies are running this type job. They buy 
doctors for the dispense their products where the company contacts the doctor and agree to 
exchange a certain amount, for example 500 specific product for travel outside Iraq for 
tourism or other type gifts, the doctor contact the wholesale directly and asking to send the  
quantity required to send it to the pharmacy who deals with in nearby area ” (Informant 
no.3) 
Another informant described the dirty job by mentioning an example about this type 
of deals between the doctors and pharmaceutical companies, informant said that:  
. ”There is not complete study about the products out of need in Kurdistan which shows that 30% of 
the physician in Kurdistan write a food supplements in their prescription to increases the price of the 
prescription about $ 20 and this money given to the doctors who rushed to take the company to 
increase the margins of the company, leading to inflated price in Kurdistan”(Informant No.6) 
One more of the informants mentioned that the “good doctors” would support the 
idea, especially, the specialists because the system would help them to get the 
expensive medications for their patients and get better treatment results. 
 
From the informants point of view, the wholesalers (pharmacists, businessmen and 
entrants to the market the wholesales have no idea about any system; they said it is 
just a business task for them to get money, it doesn’t matter how and who has 
benefits. The most important thing for them is the guarantee to get their money back-
it is just a marketing and competition matter. 
 
A gradual change is important and helpful. Many informants thought that it is not easy 
to start a new system in Iraq and the decision makers will hardly react to change the 
system, the Ministry of health would not accept any change easily. One informant 
mentioned that «the decision maker will hardly react, because it is difficult to get 
change in an old system for many years, I mean the ministry of health will not accept 
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any change easily" (Informant no.4). Some informants mentioned that the 
government could get a benefit after a while of the reimbursement application 
because of the patients’ contribution in payment in public sector which could help to 
increase the ability of the state to give better service in the health care system as a 
whole and to get a more organized administrative system to avoid corruption. 
4.3.5 Barriers for the change (Dirty Job and problems) 
Some informants talked about the “dirty job” that could destroy every change in the 
system. They mentioned the illegal contracts between the doctors and the 
pharmaceutical companies or agents and some pharmacists. For example the 
doctors get offers and gifts from these companies such as a travel ticket or money 
percentage in the margins or some expensive gifts. 
   
Other problems are the companies without any official approval (the companies 
without registration in MOH and without any quality control to their products. In 
addition, to the illegal pharmacies and entrants the MOH has no control there 
because of this type of job. The other barrier which could be very important to impact 
the change is the deficiency in the informatics Systems (IT system). The technologic 
factor is important. The building of a new computerized system to get good and 
perfect connection between actors is important.(pharmacy, registration centers, 
MOH, Banks, wholesalers). More than one informant emphasized that, for example 
the one who said:" if we can get a good electronic system and a good internet technology 
in Iraq such as Norway, I think it is the most important factor in pharmaceutical policy” 
(Informant no.7). Another informant expressed similar concerns: "get the important 
factors such as: internet and the electronic communication and the experience to use this 
type of system, I mean the electronic prescription, it is very good to start with especially in 
Iraq now, they have started electronic card of personal information”(Informant no.8). 
  
82 
 
4.4 Affordability and availability of pharmaceuticals 
in Iraq vs Norway-Diabetes case 
The availability of medications needed is the patient’s problem in Iraq, and. the 
patient self-have the responsibility to find the prescribed medications for himself to 
get treatment, either in public or in private pharmacies. According to the informants, 
the public sector tries to get the medications, but it is not always possible. Therefore, 
the patient must find the medications needed from the private sector (Community 
private pharmacy) and it is not always affordable or available for him. “about 60% of 
medications are available in the public sector e” (Informant no.8).This was true before 
the crisis in June 2014.The last interviews in December 2014  with two informants 
who expressed opinions about the availability, one of them by saying: "Nowadays, not 
all the pharmaceuticals are available in public hospitals. It has about 70% available because 
of the support of some international humanist organizations, such as UN and WHO. The rest 
of hospitals needs will be bought by every hospital from the private sector"(Informant 10) 
 
The informants generally thought  that the Iraqi government has the responsibility for 
the affordability and availability of medications because of complex and difficult 
administrative problems. The patients prefer to go to the private sector, especially the 
cancer patients.  
 
Generally, there is greater availability in the private sector for medications, but less 
affordable for patients. More than one informant mentioned that the cooperation 
between the MoH (public sector) and the private sector is necessary to get more 
available and more affordable medications for Iraqi patients. The state gives an 
economic support to the patient in case of buying the pharmaceuticals from the 
community pharmacy. One informant explained, “The private sector is very important to 
make more available and affordable medications"(Informant no.5). 
  
According to informants, the lack of medications in the area is mostly cancer 
medications and the expensive drugs which are not available in public sector. 
 
In Kurdistan the situation is completely different, due to the political situation in the 
area, the medications before the crisis are better than now, the availability was good 
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but the problem is the affordability of medications because of the dramatically 
increase retail prices of pharmaceuticals compared with the other countries. The 
dramatic increase in retail prices in Kurdistan was because of the swindles of the 
system by the pharmaceutical companies and some pharmacies. Informants 
illuminated that by “The availability of pharmaceuticals is good in Kurdistan but it’s very 
expensive to the patients, however more expensive than in neighbor countries"(Informant 
no.6) 
 
The example case in the study was the availability of pharmaceuticals in the 
treatment of the patients with Diabetes mellitus in different areas in Iraq compared 
with the Norwegian patients, regarding both the availability and pricing of different 
products that were essential and popular in diabetes treatment. In the table below 
(see table 8), the comparison is based on the available products for diabetes 
treatment in Norway (NoMA), and unpublished data from MOH institutions in Iraq, 
delivered to researcher on 01.06.2014. See appendix 5 to get a picture about the 
treatment access. 
 
The diabetes medications were focused on in this study. A list of the diabetes 
medication access and availability in Iraq was made and sent to several informants, 
who helped in filling in the needed information. There is a very large variety in the 
treatment of both diabetes type 1 and 2 in the Iraqi pharmaceutical market. There are 
many pharmaceuticals in tablet form with both the brand and the generic of 
production even at national production level (domestic production for). The general 
theoretical availability for them is that they are dispensed free of charge for three 
months per patient for Diabetes Mellitus health centers in the hospitals and in the 
public health care clinics. The amount is decided by the physician according to the 
patient response and daily dosage.  
 
It is not allowed to sell them in the private pharmacy, but this can nevertheless 
happen because of the “dirty job” described earlier. The amount delivered in DMC 
(Diabetes Mellitus centers) in hospitals is for 3 months use while in the public health 
centers is for one-month use. The variation depends on the central need committee. 
The deficiency in some items can lead to the buying of these items from the private 
pharmacies (or by dirty job).   
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Figure 14. Pharmaceuticals Access in Diabetes treatment Norway / Iraq, where √√ 
means very good access, √ means good access, X means limited access and XX means no 
access at all12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The access of Insulin in vials, prefilled pens, ampules from Novonordisk and Sanofi 
Aventis are completely the same in Norway as in Iraq but the extra rapid insulin 
                                                          
12
 VV Very good access and XX no access completely 
a) Including all types Insulin’s, rapid, and middle, long and combination action insulin’s as 
injection forms injection. 
b) Extra rapid action insulin. 
c) Biguanidderivater, sulfonamides, derivatives derivative of urea, Sulfonamides sulfonamide 
derivatives derivative of heterocyclic forbindelser.Kombinasjoner of blood glucose lowering 
drugs for oral use, Alfa glucosidase, Thiazolidinediones, Dipepitidylpeptidase 4 inhibitors and 
so on. 
d) There are many companies produce the same drug in different prices in Iraq both bran 
products and generic is available (Access) 
e) Insulin pump access in Norwegian market for 30 years ago. There are many types insulin 
pump in the market per 2014 .Insulin pump is a mechanical pump with different sizes and 
types, some of them with little slang and other without slang and have a remote control.  
f) Every diabetes patient can get blood sugar measurement device, free or with payment, 
different companies with different products access in pharmacies and hospitals, the patients 
get the devices consumable with blue prescription and they are reimbursed in price. 
g)Its partially available in the market with narrow variation ,the patient must buy it by himself 
without any insurance ,sometimes it’s available in some public institutions(diabetes clinics) 
but the patients must buy the consumables self which are partially  available in the private 
pharmacies. 
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APIDRA is not available in Iraq per 2014. Amaryl and Metformin tablets are always 
available in the private pharmacies. The appendix 5 shows that some types of 
pharmaceuticals are not available anymore in Norway such as Mixtard vial from 
Novonordisk and DaonilR 5 mg (glibenclsmide) which in Norway is available in 
1,75mg and 3,5mg only. 
 
The same informant provided the researcher with some pictures to illustrate the 
access to diabetes treatment and the access of the blood sugar measurement 
devices and its consumables. The pictures bellow provided from one of the 
informants (se figure 14.) shows two types of blood sugar devices type which access 
in the Iraqi market now only. 
 
 
Figure 15. Blood sugar devices and consumable access in Iraqi market,the 
picture from one of private drug store in Iraq in 2015. 
 
 
 
In the figure above and according to the informant and appendix 5, these devices are 
very restricted in the market. The most available one is Accu-Chek active. It’s mostly 
available in the private sector with retail price 23$ for the device and 11$?  In drug 
stores, community pharmacies and sometimes this device? Is dispensed with 
limitations and  in some hospitals. The patients mostly buy their consumables, se 
appendix 5. 
 
Pictures taken by the researcher from one of the Norwegian pharmacies illustrate the 
availability of the same variables (see figure 15). 
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 Figure 16. Blood sugar devices and consumable access in Norwegian 
market,the picture from one of community pharmacy in Norway in 2015. 
 
 
 
 
The insider pharmacist provided the study with pictures taken in January 2015 
demonstrating the availability of Diabetes treatment in one of the Diabetic centers 
institutions of MoH the public sector (see figure 17). 
 
Figure 17. Demonstrate the types of Insulin and some diabetes type 2 tablets 
that access in Iraqi market (public sector) in 2015. 
 
  
 
The researcher took a picture of the accessible Insulin in one of the Norwegian 
community pharmacies at the same period, in January 2015 (see figure 18) 
Figure 18. A picture demonstrates some types of Insulin are that access in 
Norwegian market in 2015. 
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According to the informant, the above pictures demonstrate the differences in the 
access of Diabetes treatment in Norway and in Iraq. 
 
 
According to the informant, Insulin pump is not available in Iraq per January 2015. 
According to informants from Kurdistan all the types of brand and generic of the 
international pharmaceuticals for diabetes are in the market, but" there is no access for 
any type of Insulin pump" (Informant no.11) 
 
There is Insulin in all forms (pen, vials and ampules). Informant from Kurdistan 
mentioned that in Kurdistan a special Diabetes centers access for consultations and 
treatment, these centers funded by special national human organizations funds and 
from oil funds .The patients there get regular medication free of payment. The 
patients can get simple devices for blood sugar measurement. The patients 
themselves buy - their consumables to measure the blood sugar at home. .This 
affects the good follow up for daily life to a patient with diabetes. See appendix no 5. 
 
There is no support, no reimbursement or insurance coverage to this type devices 
but it is possible to measure blood sugar in hospitals or diabetes clinics .The devices 
could be available for some people who have relatives outside the country .The 
researcher provided the study with a picture to demonstrate many types of insulin 
pumps that exist in Norway. 
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In addition, and based on appendix no. 5, a random selection of price examples of 
insulin available in Iraq and Norway are shown in the table below (see table 9). 
The examples are taken in regarding to PPP,PRP and deductible price after 
reimbursement where the patient pays 36% of the PRP (DP) in Norway in US $ per 
25.January.2015 (see Currency appendix 1 ). The prices in Norway were from the 
Norwegian community pharmacy Apotek 1. 
 
 
Example  
Table 8. Price example from appendix no 5 
 
Insulin 
analogues 
Iraq13 Norway 14 
PPP14  PRP15  DP16 PPP PRP  DP 
Novorapid flex 
pen® 3X5ml 
Novonodisk 
14.10 $ 17.5 $ 6.3 $ 35 $ 50 $ 19 $ 
Lantus 
solostar ® 
5X3ml 
Sanofiaventis 
20.32 $ 24 $ 8.64 $ 52.6 $ 73 $ 27.5 $ 
Mixtard®30 
 Vial 10ml 
Novonordisk 
 
 
 
2.3 $ Not 
available 
in private 
pharmacy 
------- Deregistered from the 
Norwegian market ,no 
more available   
 
According to the informants, there are diabetes Mellitus centers (DMC) in public 
hospitals which distribute completely free consultation and treatment for three months 
use it is free and no money included. 
 
The table below shows a summary comparison based on both literature research and 
the result from the qualitative study to explain the Nordic model and the current Iraqi 
pharmaceutical model (see table 9).
                                                          
13
 Price currency in US $ (se currency appendix)  
14
 Pharmacy purchasing price  
15
 Pharmacy Retail price 
16
 Possible future deductible price 
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Table 9. The most important categories of the Nordic pharmaceutical model and the current Iraqi pharmaceutical model 
2015. 
Category Denmark Finland Norway Iceland Swedish Iraq 
Pharmacy 
margins (PM)  
PM regulated by law 
in the form of a 
linear mar-up based 
on a dispensary fee 
added to the PRP of 
each package. 
Margins are 
digressive 
pharmacy 
margin scheme 
for all 
pharmaceuticals. 
They are 
regulated via a 
statuary markup, 
applicable for all 
pharmaceuticals, 
except NRT 
products.  
PM consist of 
a percentage 
markup based 
on the PRP 
and a fixed 
amouCnt per 
package. 
Wholesaler price up 
to 11.999 ISK, => 
retail margin 11% 
plus 868 ISK.   
 
Wholesaler price 
12.000 ISK or more 
=> retail margin 2% + 
2.050 ISK. 
Margins is regulated 
by statutory 
regressive margin 
scheme 
Not regulated 
by law, 
individually 
differences in 
private sector  
Average of 
pharmacy 
margins in % 
(profit) 
21,8% 
 
23% ~20 % Not known ~20 % Varies 
between 30-
35% or more 
 
Legislation Pharmacy ownership 
is restricted to 
pharmacists and the 
multiple ownership is 
not allowed. No 
pharmacy chains 
established. POM 
are dispensed by 
community 
pharmacy including 
branch pharmacies 
and supplementary 
pharmacy. 
98% of all 
community 
pharmacies are 
privately owned 
by pharmacists. 
The university 
owns 16 branch 
pharmacies. 
81% of 
pharmacies 
are In 
ownership of 1 
of the 3 large 
pharmacy 
chain, each 
vertically 
integrated with 
pharmaceutical 
wholesaler. 
POM mainly 
dispensed by 
Pharmacist and 
license holder must 
be professionally 
responsible for the 
pharmacies 
operation. 
The new legislation 
2/3 in hand of private 
company, the rest is 
still owned by the 
pharmacy which is 
state-owned, so it is 
allowed for both 
public and private 
establishment of 
pharmacy. POM 
dispensed by 
community 
pharmacy, private 
Pharmacy 
ownership is 
restricted to 
pharmacists in 
theory but the 
entrants have 
a big role in 
pharmacy 
business.  
No pharmacy 
chains. 
Every 
pharmacist 
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community 
pharmacy and 
hospital 
pharmacy. The 
system is de-
regulated. 
and Apoteket owned 
by the state. 
can have an 
independent 
pharmacy with 
his/her name. 
Availability and 
delivery at 
pharmacy 
level 
Almost all 
pharmaceuticals 
should be available 
immediately if this is 
not possible; it 
should be provided 
to the user within a 
reasonably being 
defined as less than 
24 hours. 
Have regulation 
regarding the 
pharmaceutical 
to be in stock. In 
general the 
majority of 
prescription can 
be filled 
immediately at 
maximum 24 
hours 
There is a law 
requirement 
availability 
medicine for 
the consumer 
within 24 hours 
Registered 
pharmaceuticals 
should in theory be 
available immediately 
if this is not possible; 
it should be provided 
to the user as soon as 
possible 
Almost all 
pharmaceuticals 
should be available 
immediately if this is 
not possible, it 
should be provided 
to the user within a 
reasonable time 
being defined as 
less than 24 hours. 
Not regulated  
No obligation 
recommended 
in law. 
Wholesaler 
margins  
Not controlled based 
on the agreement 
between a 
wholesaler and the 
manufacturer 
Not controlled  Wholesaler  
negotiation 
their margins 
with 
manufacturers 
,the lowest 
margins in EU 
Maximum price 
should in general 
(with a few 
exceptions) not 
exceed the average 
price in the other 
Nordic countries 
Fix percentage 
margin 
About 10-15% 
Pricing system 
and 
reimbursement 
Reference price 
system 
No reference 
price system  
No reference 
price system 
Reference price 
system 
Reference price 
system reviewed 
four times a year  
Not available  
 
Ceiling set to 
patient 
payment per 
year 
Yes(exemption cart ) Yes(exemption 
cart ) 
Yes(exemption 
cart ) 
280 $ / year 
Yes(exemption 
cart)311$-470.42$ 
Child/elderly/disabled-
adult  
Yes(exemption cart 
)about 216,79 $/ 
year 
Not available  
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5 Discussion  
The results of the study will be discussed in this part: first, the main findings of the 
study will be discussed, similarities and differences, with what other researchers 
have found. Then, the strengths and the weaknesses of the methods will be 
discussed and .finally, suggestions for future research and action are given.  
 
 5.1 Summary of main results  
The results from the literature review showed that there was simply meagre literature 
on the issue of pricing and reimbursement of pharmaceuticals in Iraq. Therefore, an 
explorative study was needed on the system. In addition, a feasibility study for 
restructuring and reforming to increase the availability of medications was required to 
map the possibility to apply the Nordic pharmaceutical pricing and reimbursement 
model for Iraq. However, any reforming must be realistic and practical. This is to give 
complete benefit to the Iraqi patients with pharmaceutical system, better availability 
and affordability of pharmaceuticals as well as more effective treatment of diseases. 
 
The study showed that the pricing system and state support for patients differs 
between the private and the public sector in Iraq. The current system in the public 
sector seems in theory to be good for the patient, but due to continuous 
underestimations of the need, coupled with stock-up and dirty-job spillover to the 
private sector, shortages of medicines are frequent. It is hard for patient´s’ economy 
the in private sector because of the absence of the state support for the patients in 
this sector (no reimbursement in retail price for pharmaceuticals in private sector)  
 
The qualitative interviews indicated that all the interviewees were positive towards a 
change, but several barriers were recognized such as the political situation, 
corruption and the “dirty job”. In addition, many requirements need to be met in the 
current pharmaceutical system in Iraq as a pre-condition to the change toward the 
pharmaceutical reimbursement.  
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Finally in the diabetes case availability and accessibility in Iraq was compared to 
Norway. This showed that the treatment of diabetes in both types (Diabetes 1and 2) 
seem to have lower quality and availability in Iraq, as compared to Norway when it 
comes to Insulin treatment with insulin pump and the follow up of  the daily blood 
sugar measurement. In addition to life style advices are given. The suitable food for 
diabetes patients is more available in Norway than in Iraq due to high level of 
information about the disease and the organized treatment for this group of patients 
in Norway .Both Norway and Iraq have diabetes organizations but the one in Norway 
has an important function in the patient’s life to coordinate him in different methods, 
such as information, decision making in reimbursement process by the HTA bodies, 
research support in Diabetes area and so on. The Diabetes organization in Iraq has 
restricted function.  
5.2 Discussion of the results 
5.2.1 Discussion in relation to existing literature  
 According to another study on pricing and reimbursement in UAE (The United Arab 
Emirates) from 2012, the UAE invited international service providers to manage its 
facilities and established high standard in health service delivery special 
pharmaceutical system and private sector participation increased over the years 
(Ghaleb Ahmed Al Ahdab, 2012). Therefore it can be argued to be important to 
explore other health care systems.  
 
A study from the strategic research and communication centre in Syria was published 
in 2012. It is about reforming feasibility of health care system in Syria and concluded 
that, the health care reforming and establishing of a new health care policy in Syria is 
critically important, not just to improve the physical and mental health of the people 
and enhance their sense of wellbeing, but also can improve the economic quality of 
the service. Realizing  all the challenges to reform an old health care system to 
improve the future of the Syrian state and the Syrian people are not only the 
responsibility of the government but of: universities, scientists, the private sector and 
the Syrian people themselves (Safwan Kassas & Ammar Kahf, 2012). The Syrian 
study is in line with the result in this study, regarding cooperation and contribution of 
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different actors and the patient himself, - that cooperation between all stakeholders is 
needed in order to develop and implement a reform. 
 
Another study in was done in Syria on the health care financing to map the 
satisfaction with the current public health care system. The study concluded that 
there is a need for health reform and that Syrian people are willing to support a 
national health insurance scheme. This satisfaction study was done to examine the 
willingness to participate in national health insurance ( co-payment) (Mershed, 
Busse, & Ginneken, 2012). 
 
The cultural similarity between Iraq and these countries(Syria and UAE) and the 
similar challenges in this region can  make similarities in the  project and aim in the 
same direction toward reforming and establishing of a new pharmaceutical system 
policy in the future for Iraq.  
 
This study was the first one in this direction, to explore the reimbursement direction 
for patients in Iraq, but according to the efforts of the Iraqi MoH in Iraq, there were 
cooperation between the MoH in Iraq and WHO through many meetings to sign the 
Country Cooperation Strategy document for (2012-2017) CCS. The aim of these 
efforts was to ensure the achievement of health care system policy development to 
get better and to ensure the right of health to all Iraqis (IMoH, 2014; WHO, 2014). 
 
An American study on the health care system in Iraq in November 2007, mentioned 
“the dirty job” problems in pharmaceutical system and  market in Iraq (Munro, 2007). 
The study supports my findings about the "dirty job". It already existed then in the 
pharmaceutical market and it is still corrupting the pharmaceutical policy. Moreover, it 
could be one of the most common problems. It can prevent the success of the new 
pharmaceutical system because of the corruption and unsafe conditions. 
  
This feasibility study can be the first step for Iraq toward the change and 
development in pharmaceutical policy toward pharmaceutical pricing and 
reimbursement Nordic model.   
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5.2.2 The potential feasibility of the Nordic pricing and 
reimbursement model for pharmaceuticals in Iraq 
The answer to the study’s aim is positive, the change can happen, but many efforts 
are needed. Some points in the Nordic model must be adapted to the Iraqi people. 
The most important point is the high taxes in all levels in the system. For example 
there are high taxes in wholesaler, pharmacies as well as the manufacture and 
import level of pharmaceuticals compared to Iraq. 
  
Change in a pharmaceutical policy is needed and further future feasibility study and 
qualitative studies are required to complete the result of this study. There were trails 
toward the change in pharmaceutical system in Iraq; some informants mentioned 
examples about that but the corrupt political situation for Iraq stopped that. 
 
The feasibility answer to this system is that it could be very good for patients because 
the patient can get help and economic support not only in the public health care 
sector, he will get it in private sector also. It could improve the availability and 
affordability of medications for all the Iraqi people. However, it will be difficult to apply 
the Nordic model because the study informants confirmed that the Iraqi patients used 
to use an old system, especially in regarding to free paying of medications in the 
public sector. 
  
Many requirements need to be met to achieve that and the conditions and schemes 
adaptation is necessary. It could be a good system for certain types of low income 
patients the private sector only, but the services must improve. The pharmaceutical 
system is a type of insurance system, there is a complete stately support in the public 
sector, but the availability is bad. In the private sector, there is no support. The 
patient must pay by himself. There is a type of a new start of co-payment trials in 
Kurdistan only. I think it could be the first step towards a better and more including 
reimbursement system in Iraq. 
 
The application of a new payment pharmaceutical system (reimbursement) similar to 
the Nordic one with  availability of medications and high quality of pharmaceutical 
service is difficult to apply in Iraq because of the ”trust” problem between actors i.e. a 
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reliable system is needed for the pharmacy repayment  from the state. The present 
bank system and financing process for reimbursement will be big problem in the 
absence of advanced computerized and electronic registration. Reliable and safe 
connections between different actors are needed, in order to be able to use 
electronic prescriptions and billing. 
 
There is a need for a deeper feasibility study and future research regarding patients’ 
reactions and patients’ points of view. The informants said that the defect in the 
budget from the oil fund could alone lead to direct defect in the health care service in 
public and semi-public sector. Moreover, this is one of the most prominent and real 
problems in the pharmaceutical system today especially in public sector related to 
the chronic diseases treatment. The mono-resource for pharmaceuticals 
procurement budget could be one of the most important factors, which affect the 
availability of medications in public sector. In case of the budget defect it could cause 
a defect in the pharmaceuticals availability simultaneously. Therefore it is better to 
find a better resource for a better procurement such as patients’ co-payments or 
taxes, but not high level of co-payments. This low level of patient co-payment in 
public sector could help the state to reimburse the medications in private sector also. 
Moreover, this would give benefit to the patients in case of a need to buy the 
medication from the community pharmacy also. 
   
The “dirty job” is one of the problems that can destroy a new system implementation 
in Iraq. This problem has been noticed from the period after 2003 in the 
pharmaceutical Iraqi market. It had been documented by USAID (Munro, 2007) .The 
term "Dirty Job " in the field of health care system in Iraq, is defined by the people 
there as;  the illegal behaviour of the healthcare professional inside the public sector 
institutions such as nurses and physicians and other health care staff; the patients 
illegal abuse of medications by selling it to get money and finally the pharmaceutical 
companies illegal business in Iraq. 
 
Other problems and disadvantages of the fee free pharmaceutical system is that 
there is a big chance of abuse of the medications by patients and other users 
especially in public institutions because it is free of charge to the patients, there is 
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large waste of resources and only prescription pharmaceuticals (Al-Hemiary, Al-
Diwan, Hasson, & Rawson, 2014) 
 
The bad availability and affordability was the most prominent problem to the Iraqi 
patients both in Kurdistan and Iraq especially in Iraq, the informants confirmed that.  
The solution according to the informants is to increase the availability of 
pharmaceuticals and to establish pharmaceutical reimbursement system to support 
the patients in the private sector in addition to providing more economic support to 
the health system by taxes and low level of patient-payment. 
 
In any case it seems to be better medications availability in Kurdistan but expensive 
and the change in pharmaceutical policy has already happened there. The chronic 
diseases medications can be obtained just for 1-5$ for 3 months use from the chronic 
diseases health care centres, while in Iraq, its just 500 ID=0.42 $.  
 
The security and the political situation in Iraq are very important to offer stability in 
Iraqi pharmaceutical’s market and can affect both the availability and affordability of 
pharmaceuticals to the Iraqi patients.  
 
The results shows that there is a destruction of medication supplement in Iraq 
especially in public sector which makes the patients go to the private sector, some of 
the informants thought that the solution of this problem is to increase the generic 
medications to make pharmaceuticals more affordable. This might indicate that any 
change needs cooperation between different actors and patient to see the result just 
trying to initiate a change. 
 
One informant thought that the political situation in Iraq and the pharmaceutical policy 
have a dramatic effect on any change in the system. I agree with this opinion 
because this could indicate that, the change must start with the reorganization of the 
private and the public sectors in order to get more stable pharmaceutical pricing 
system. As a result of the difficult and inaccurate procurement system, and  lacking 
precision in estimating the pharmaceuticals needs every year,  a shortage of some if 
not most of pharmaceuticals in public sectors existed. 
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5.2.3 Is it only to copy and paste the pharmaceuticals Nordic pricing 
and reimbursement model? 
Possibly, it could be difficult to copy and paste the Nordic model directly to Iraq but 
the adaptation is necessary. The study indicates that there were disadvantages and 
problems with the Nordic pharmaceutical model for Iraqi people and these problems 
might be avoided. The main problem was that the Nordic system (Norwegian ) is 
advanced and complicated to apply in Iraq regarding technology and advanced 
authority system (Helsedirektoratet, 2009).  
 
The other problem was that the patient acceptability to the price level in 
reimbursement phase (example Novrapid flexpen 3X5ml is free of charge in public 
institutions but it costs the patient about 6.3 $).It could be difficult for the patients to 
pay 36% or possibly any patient co-payment in public sector, especially at the start of 
the a new reimbursement process. The reimbursement price level could be helpful in 
other pharmaceuticals examples, like the expensive ones. 
 
So, it is possible and necessary to inform the Iraqi patients about the aim of 
reimbursement in private sector and low level patient co-payment in the public sector. 
It is necessary to inform the Iraqi patients about the pharmaceutical reimbursement 
to get full and complete availability and complete treatment benefits without any gap 
or absence of the decided treatment due to the availability problem. 
 
The study shows that the prices in private sector could be high for the Iraqi patient, 
but the margins percentage of pharmacists and pharmacy appears to be higher in 
Iraq than in Norway. 
 
There are other important differences between the pharmaceutical systems in Iraq as 
compared to Norway, for example the possibility to get all the medication by the 
same system in both community pharmacy and the hospital pharmacy. In Norway, 
there is no public sector like in Iraq, but inpatients in hospitals get medical treatment 
there.  The private sectors in both countries have similar setup, apart from the 
reimbursement part. This could affect the availability of medications positive 
regarding to the patients need and facilities.  
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(I.e.as a patient in one of the Nordic countries, one can get his treatment anywhere in 
the country and every community or hospital pharmacy has responsibility to provide 
the patient order of pharmaceuticals within 24/48 hours ). While in Iraq, the free 
public market of pharmaceuticals completely separated from private market. In 
addition to that, the unstable availability in the free public market in Iraq could give 
dramatically reduction in the effectiveness of medications and the treatments 
efficiency. 
 
In theory and according to the Iraqi law the patient must get insulin and other chronic 
disease medications for free, but what if there’s a defect in the availability, so the 
patient might buy it from the private sector (community pharmacy) for full price and 
this could happen often in Iraq because of the political situation.  
5.2.4 The requirements needed to get new pricing and 
reimbursement system for Iraq in comparing with Nordic countries 
According to the results of qualitative interview of the study, all the interviewees gave 
the impression that a change in the current pharmaceutical system is necessary, but 
there are many requirements needed to get a new pricing and reimbursement system 
for Iraq in line with the Nordic pharmaceutical pricing and reimbursement, and I agree 
with them. 
• “Trust” between the different actors. Example: pharmacists, wholesalers, 
pharmaceutical companies, banks and government in order to guarantee the money 
repayment to the pharmacist as a type of pharmacy business. 
•  Time factor needed to get a trial reimbursement system in place of the 
current system in some cities and pilot pharmacies can be helpful. 
• Fix margins value in private pharmacies as in the Nordic countries, new 
pricing policy needed according to the international models. 
• Low level co-payment from the patients as a type of civil cooperation in 
public sector   to get better service as in the Nordic countries with taking into account 
the economic ability for payment and may be adapt the Norwegian reimbursement 
model with suitable deductible percentage in private sector. 
•  Patient’s agreement to accept the co-payment needed. 
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• More organized administrative system needed to reduce the corruption in 
the pharmaceuticals area. 
• Good contracts and guarantee between the government and the private 
sector needed. 
• Reduction of the entrants and the “dirty jobs” which are the biggest 
problem, therefore it must be reduced to the level of the Nordic countries to protect 
profession rights and the job regulation in pharmaceutical market.  
• The computer systems in Nordic countries have a successful method to 
make the distribution and the direct sale of pharmaceuticals easy and documented 
by using advanced software programs such as Pharma-Pro17 in Norway (Clickindia, 
2015). The same computerized system needed in Iraqi pharmaceutical market 
(wholesale, pharmacy and authority). 
 
5.3 The choice of the method 
In the following part of the study, the strengths and the weaknesses will be discussed 
by discussing the selected methods, and then assessing the quality of the interviews 
from the concept of validity, reliability and generalizability of the results.  
 
This is the first study in Iraq with pharmacists as stakeholders and in spite of the 
technique problems with the internet collection, the data needed to answer the issue 
of the project was collected. In addition to the misunderstanding (which was one of 
challenges in the interviews) of one of my informants from Iraq about the 
reimbursement system and insurance system. Some informants gave me new cues 
that motivated me to recruit a new informant who gave me more data with more 
benefits for the project. 
 
The aim or the purpose of the study decide which type research methods can be 
used (Malterud, 2011). The study was carried out in Norway, but it could be better if it 
had been partially carried out in Iraq to have higher validity. More than one method 
was used; qualitative method because the aim of the study was partially a community 
                                                          
17
 Pharma-Pro definition in page 14 
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research and qualitative methods are suitable for in-depth understanding of 
phenomena, including phenomena that little is known about, and in depth-
understanding was the purpose of the study.  
 
Interviewing stakeholders in order to collect data on phenomena that little is known 
about, is an approach that has been used previously in Burkina Faso and in Iceland. 
An article from Tropical Medicine and international health from 2006 describes a 
study about Burkina Faso health system (Haddad et al., 2006). Another  study from 
2008 describes the feasibility to apply the Swedish model to value- based price of 
pharmaceuticals in Iceland (Björnsdóttir, 2008).Those studies used the same method 
of qualitative interviews that sparked the researcher’s  interest in  in using the same 
approach.  
 
The strategy of the study method depended on the qualitative method to explain the 
topic characteristics and describe the meanings and thoughts about the topic issue, 
because of the materials of the study were interviews and text the qualitative analysis 
was the suitable method to choose (Malterud, 2011). 
 
In this study, a mixed methods approach served to answer the research question. 
The use of qualitative semi-structured interviews helped the researcher to ask 
clarifying questions which helped to ensure that the topics in the interview guide was 
exhausted. This type method could be better if the focus group interview be used at 
the same time for better discussion and could help to get more attitudes and 
experiences from the informants but it was not possible due to the project location 
and the researcher travel restrictions. In addition, the number of informants could be 
more but the time restriction and the busy days for informants (pharmacists). A 
higher number of informants could be increase the validity of the research in general. 
My last two interviews in the study in December showed that data appeared to be 
saturated (no new information added), so it can be argued that I did not need more 
informants. In addition, in qualitative studies, the high number of informants is not 
always an indicator to the creditability and validity of the study (Morse, 2000). 
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5.3.1 Informants and recruitment 
Initially 20 informants had been recruited and invited to participate. It was desirable to 
strength the validity of the study. They were from Norway, Denmark, Sweden and 
Iraq, but only nine wanted to participate. Invitation letters were send to nine 
pharmacists from Nordic (Sweden, Norway and Denmark) with Iraqi background, but 
just 2 of them wanted to participate, two responded with ”no”, four did not respond 
and one answered  “yes” but pulled back .On the other side, eleven Iraqi pharmacists 
from Iraq had been recruited and invited, but only seven of them wanted to 
participate, two answered with “no” and two did not respond. In December, two of 
Iraqi respondents responded by mail and were willing to participate. The sample area 
of the study in Iraq is demonstrated by figure 19 below. 
 
Figure 19.Map of administrative division of Iraq and the including / excluding 
area of the study.  
 
 
 
In the figure above (see figure 19) the red color shows the division area of Iraq 
included in the study ,the gray color shows the excluded area from the study (crisis 
area) and the green areas have the same criteria for the red area and the same 
conditions  and the study could be used or generalized there. 
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To do the qualitative interviews, respondents were recruited, with basically 
pharmacists and professionals who know what is going on in the pharmaceutical 
system in Iraq and Nordic countries’  and have knowledge about pharmaceutical 
pricing and reimbursement system. An attachment  including an Executive summary 
about the Nordic pharmaceutical system was send to make that easy to the 
informants from Iraq.   
 
Nevertheless, the challenge was that not all informants had time to read it, so I might 
inform them in the introduction of interview or within the interview time. Pharmacists  
 
from Iraq were included who have diverse mix of knowledge from different 
pharmaceutical sectors, and from different geographic regions in Iraq (North, south 
and middle); such as pharmacy leaders, whole store owners, academies, some of 
the informants have a children with Diabetes type1. 
 
Data saturation was achieved and nothing new added by the last informant .The data 
saturation is achieved when there is no new information coming by informant and the 
interview repeated (Malterud, 2011).The number of informants was not high but the 
credibility of them was high because most of them were decision makers and 
academics with long practice in pharmaceutical area. 
 
An important criterion for good research validity is that  the informant feels safe as 
regards sensitive information and their identity (Steinar Kvale & Brinkmann, 
2014).The informants were informed about the anonymities to make them safe and 
talking freely during the interview. It could also have been preferable if the interview 
had taken place in the informant office, but it was difficult and the interviews take 
place by Skype, relying on Skype’s stated policy for safety and privacy.  
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5.3.2 The interviews  
The researcher (interviewer) was new in this area, the qualitative research area, and 
was restricted to the interview guide especially in the first interview. The interviewer 
was relatively inexperienced in an interview situation and this could make the validity 
weak especially at the beginning of the first interview. After a couple of interviews 
were conducted, the situation became more accustomed and there was more ease to 
listen and to discuss the informant’s answers.  
  
 All the interviews had the same interview topic guide main questions (Steinar Kvale 
& Brinkmann, 2014). The interviewer was as neutral as possible in order not to affect 
the answer of the informants, but the lack of research experience as interviewer can 
possibly have affected the informants.  
5.3.3 Transcription 
The transcription of the interviews was done soon after each interview either at the 
same day or at the next day. The sound was clearly recorded by help of speakers. 
The sentences were clearly pronounced in the researcher mother language (Arabic) 
or in English for some terms and words. All the interviews had been listened four 
times to ensure that everything had been written down correctly in transcription and 
written in Arabic text and translated to English as a whole. The same person (me) did 
all the process, transcription, translating and analysis with help of the supervisor in 
the technique. The translation has been done by the Microsoft translator in word 
program and by the researcher.   
5.3.4 Analysis 
This part of the study was the most time consuming, and efforts to work with the 
interviews, listening many times, transcription and translation before the analysis 
process were quite tedious. In qualitative interviews , the interviews must be 
transcribed, listened to and read many times to get the overall impression of the 
information (Patton, 2005).  
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The analysis of interviews was done with meaning condensation, which is a strategy 
for analysis of qualitative data. Meaning condensation is a descriptive and explorative 
method for thematic extraction for different types of qualitative data such as interview 
studies and analysis of written text with four steps procedures to get the final 
description and concept of the qualitative analysis meaning (Steinar Kvale & 
Brinkmann, 2014; Malterud, 2011). 
The same person did the analysis. Here several researchers’ opinion could have 
increased the validity of analysis. 
5.4 Validity 
The validity describes how well founded and useful the results of the study are. The 
importance of validity in the study is to ensure that the results can be used effectively 
in the future research and that we use the information from the study (Morse, 2000). 
It is also necessary to assess the researcher’s skill and credibility which also has 
influence on the quality of the results/data (S Kvale, 2009).The validity of this study is 
depending on the finding of reasonable conclusion. Although the communication 
validity and dissemination of information between informants and the researcher was 
valid because the researcher have the same mother language and the dissemination 
of information was high in the interviews. This study can be useful in Iraq to improve 
the pharmaceutical system.  
5.5 Reliability 
The reliability of the study describes the result accuracy and if the results could be 
used by other research at other time or in the future (S Kvale, 2009). The method of 
the project is to use the interview with semi-structure topic questions. It could be 
useful to other researchers with the same methods. 
5.6 Generalizability  
According to the project results, it will be relevant to look at weather these results can 
then be applied and generalized just in Iraq. The response to the reimbursement 
system in the different areas could differ, according to a variety of conditions. There 
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is no guarantee at the project results that can be generalized to all of Iraqi’s regions. 
They apply to some of them, such as Kurdistan, and some politically stable cities in 
Iraq such as Najaf and Karbala. The result cannot be generalized in other countries 
because the data and the informants dealt with the application of the Nordic 
pharmaceutical system in Iraq. It is generally difficult to generalize? qualitative 
research because of the low number of informants (Malterud, 2011). 
5.7 Future recommendations, action and research 
Iraq does not lack the intellectual and economical capital needed to start 
pharmaceutical service research and development, but Iraq lacks the stability right 
now. The government can take action to provide a new development trails and 
research in pharmaceutical pricing and reimbursement models existing in the world. 
Very few Middle Eastern countries have realized the importance of pricing and 
reimbursement models such as (UAE and Turkey examples). In addition to that, the 
government can take action in pharmaceutical policies to encourage greater 
intellectual interchange between Iraq and the international reimbursement model 
providers. 
 
New pricing and reimbursement system needs to be established in Iraq by local 
/regional research. New pharmaceutical regulations, authorizations and policy are 
needed in the future. Training of highly qualified pharmaceutical system managers 
and administrators where the pricing evaluation can be analysed skilfully and 
professionally in addition to in service training needed about the pricing and 
reimbursement to increase the expertise in this area. IT systems modifications, 
development, and automation of the prescriptions and the communication / E 
prescription and new pharmacy retail software are required. Government can take 
action to establish national electronic information system and an electronic 
transection of payment is important to access. 
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6 Conclusion 
There is a need for pharmaceutical pricing system and payment reforming in Iraq 
according to the pharmacists, since all the Iraqi patients have a human right to the 
principle of the rational use drug. The Iraqi people need to change or improve the 
current pharmaceutical system to get better health in the future.  
 
• All the interviewees from Iraq and Norway believed that there are possibilities 
to apply a new pharmaceutical pricing and reimbursement system in Iraq, but 
gradually. The study shows that the change in Iraq has already started as a 
first step toward reforming of the pharmaceutical pricing system in some parts. 
• Iraq has the intellectual and economic ability to get a better pharmaceutical 
system, but many requirements are needed, e.g. if using the Nordic model an 
adaptation of the Nordic pharmaceutical pricing and reimbursement models is 
necessary.  
• Iraq is in need of changing or improving the pharmaceutical system policy and 
modernization of the computerizing system to improve any change toward the 
pharmaceutical Nordic model before any change.  
• According to respondents, other barriers to be overcome before being able to 
implement such a system are for example: especially of the “dirty job” among 
physicians and pharmaceutical companies and the abuse of the free public 
system and the transfer of pharmaceuticals from the free to privatized system. 
This part of the problem might be partially or fully solved with some sort of 
good surveillance system. 
• The current Iraqi pharmaceutical model can be good regarding to the public 
sector in related to the cost free medications in this sector. Nevertheless, the 
inadequate availability of pharmaceuticals is a problem for the Iraqi patients. It 
could be better for Iraqi patients to get economic support for pharmaceuticals 
in the private sector as well i.e. a more comprehensive pharmaceutical 
reimbursement system to reduce the cost for patients in private sector. In this 
way, it will be better availability and affordability to the patients according to 
the rational use of drug principle. However, there is a probably a financial 
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issue and new financial models are needed with sharing in payment between 
the state and the patient in private sector. 
• Further feasibility studies and efforts in the future are recommended to 
manage to come up with new successful solutions to introduce new pricing 
and reimbursement model in pharmaceuticals to improve the health service to 
Iraqi people.  
 
During the time of the study, it was clear that the situation in Iraq was more 
concerned about the security and the political stability. Therefore, possibly the 
solution could be mostly the political stability, or preventing spillover from free public 
system to semiprivate system with taking into consideration the low level of patients 
copayment in the public sector and private system with reimbursement and economic 
support. More feasibility studies of pharmaceutical reimbursement in Iraq in the future 
are needed to solve these issues. 
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Appendix 
 
Appendix 1 Currencies exchange rate  
 
Exchange rates published on 20.January .2015 by the Norwegian Central Bank  
 
Currencies  Currency / 1 Euro € 
AD 1.14 
DKK 7.46 
ID 1339 
NOK 8.8 
SEK 9.33 
ISK 152.01 
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Appendix 2. Invitation letter for interview and consent for participation  
 
Invitation letter to the study 
Feasibility of the Nordic pricing and reimbursement system for Iraq 
-Norway as a case 
Dear ___________________________________ 
My name is Ashwak Hamza and I am a master student at the School of pharmacy, 
University of Oslo. I am conducting a research study, where I am studying the 
pharmaceutical reimbursement systems and regulation of pharmaceutical prices in 
the Nordic countries (Norway, Sweden, Iceland, Finland, and Denmark) and in Iraq. 
The study aims at exploring the potential feasibility of Nordic pricing and 
reimbursement model for pharmaceuticals in Iraq. I hope that both the Iraqi and the 
Nordic society will benefit from the study results in the future, especially patients in 
Iraq in need for costly medication for treatment for chronic diseases. 
With this letter I want to invite you to be interviewed about the topic. The interview will 
take place by Skype\ telephone, and it will be audiotaped so that I can analyze the 
discussion. The tapes will only be reviewed by members of the research team who 
will transcribe and analyze them. The use of Skype will be secure according to Skype 
legal privacy policy http://www.skype.com/en/legal/privacy/  and they will then be 
deleted.  
You don’t have to answer any question that you don’t wish to. It is voluntary to 
participate in the project, and you can at any time choose to withdraw your consent 
without stating any reason and participation is confidential. Study information’s will be 
kept at a safe location at the University of Oslo. The result of study will be published 
but without any identifiers for individual informants. Date of project completion will be 
in 31.05.2015. Don’t hesitate contacting us if you have any further questions or 
concerns. You may contact me or my first supervisor Ingunn Björnsdottir, Associate 
Professor at the Department of Pharmacy, by telephone: +47-22856650 or email: 
ingunn.bjornsdottir@farmasi.uio.no  
Thank you for considering to participate, it would mean a lot to me. I will call you 
within the next week to see whether you are willing to participate. 
Sincerely, 
Ashwak Hamza 
Telephone: 004745038251 
Email:hamzaak@student.farmasi.uio.no 
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The study has been notified to the Data Protection Official for Research, Norwegian Social Science 
Data Services,(NSD). 
 
 
Informed consent for participation in the study  
Feasibility of the Nordic pricing and reimbursement system for Iraq 
-Norway as a case 
 
I have received information about the project and am willing to participate                                                
o I agree to participate in the interview 
o  
o  
o  
------------------------------------------------------------------------------------------------- 
(Signature and date)  
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Appendix 3. The interview topic guide 
 
 
Feasibility of the Nordic pricing and reimbursement system for Iraq 
Norway as a case 
Interview guide for my informants in Iraq and in Norway 
 Pricing model: 
Please describe, how prices of pharmaceuticals (medications) and also how the 
margins (mark-up) in Iraqi community pharmacies (private) and public pharmacies    
 
How do you think the pricing system of medications (pharmaceuticals) works today? 
(Who benefits and who does not?) 
To what extend (as a pharmacist) do you think the pricing system of medications now 
could be changed in future? What is the best method (way)? 
Reimbursement system  
What comes to mind when I say “reimbursement”(medical insurance )? What other 
terms could be used regarding similar arrangements in Iraq? Can you describe the 
reimbursement system (the health care service, medications, and co-payment) for 
patients in Iraq today? 
How do you think the medications system (pharmaceutical reimbursement) works 
now? (How could it be improved, who benefits and who does not?)  What do you 
think is needed to be done in the future to help patients get more affordable 
medications in private pharmacy? How can Iraqi public health system secure the 
medications availability for the patients? 
Do you think changes can happen to develop pharmaceuticals policy (medications 
system) in that direction (I mean the medications/pharmaceuticals reimbursement 
direction) in the near future in Iraq? 
Did you find time to read the attachment information about the Nordic reimbursement 
system? If the answer is (Yes); what do you think about the Nordic reimbursement 
system, feasibility of it for Iraq? 
 
How do you think different actors would react to this idea e.g. community, pharmacy 
(private pharmacy), governments, and patients? 
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  noitpircsnart fo elpmaxE .4 xidneppA
 
 dna ledom gnicirp lacituecamrahp gnidrager ,K htiw weivretnI
 .qarI ni )tnemesrubmier( metsys lacituecamrahp
 kawhsA ,reweivretni=SA      tnamrofni= //  == K   4102.90.40 ,yadrutaS
 azmaH
 imes a(  natsidruK ni ycamrahp scinilc tnalusnoc eht morf tnamrofni ym fo noitalsnarT
 rh 70,1 ewivreti fo emit                       )renwo ycamrahp etavirp
 no  rotalsnart tfosorciM no gnidneped saw gnittesrevo rof dohtem euqinhcet yM
 ym rof gninaem thgir eht teg ot gnidnatsrednu cibarA ym dna margorp 0102 drow
 eht teg ot noitalsnart hpargarap eno yb enod saw noitalsnart ehT .tnamrofni
  .sgninaem etarucca tsom dna etamixorppa
 
  في بداية المقابلة حاولت اذكر بعض النقاط للمشرك ورغم ضعف النت والصوت لكن تم التسجيل والبدء بالمقابلة بما يلي يلي
 ١-ستكون المقابلة غير معلنه 
 ٢-شرحت مقدمه مختصره عن البحث وتسميته والنظام الدوائي والتسعير في الدول الاسكندنافيه 
 ٣ - وضحت ان لغة المقابلة يختارھا اللغه عربي -إنكليزيه - نرويجي 
 ٤- الحوار سيكون  حر 
 ٥-قد يحصل خلل فني فيتم اعادة الاتصال 
 المشارك  كان مشغول بالأجابه علي التلفون وھو مدير لقسم الصيدله في دھوك التابع لوزارة الصحه في كردستان 
 آشواق : ممكن تقدم نفسك ؟ 
ميرخان : انا الصيدلاني ميرخان ابو صالح مدير قسم الصيدله في دائرة صحة دھوك وكنت منسب للعمل في منظمة الصحه العالمية 
املك صيدليه واديرھا في القطاع الخاص وعملي يدخل ضمن العّياده الاستشارية  كان عندي صيدليه عاديه وبعدھا تحولت الى 
العيادات الاستشارية المحدودة الأرباح والأسعار الصيدلي محدد بربح ب ٢١٪ فقط وھي عيادات منخفضة التكاليف لكل الخدمات 
 التي تقدمھا للمرضى وبأجور مخفظه .
 ? بمعنى اخر ycamrahp siht ni dediced lacituecamrahp fo secirp eht woh ebircsed esaelpاشواق :
 كيف يتم تحديد أسعار الادويه في ھذا النوع من الصيدليات؟ 
ميرخان:مقدمه البولي لكنك ھي سمي برايفت وليس برايفت تخضع للحكومة وانا عندي تعليق على ھذا النوع لان المريض يضيع 
حقه فيھا لان الأطباء في العراق وكردستان ودخلت شركات الادويه التي تركز على الدعايات للمنتجات ... رغم كونھا جيده من 
 ناحية النضافه والموقع والبنايات الحديثه والأثاث والتجھيز الحديث لكن فيھا استغلال للمريض وأحيانا سؤ ء استخدام للنظام الدوائي 
 اشواق : انقطع الاتصال وبدا اتصال جديد 
 اشواق : لماذاانت غير مرتاح لھذه التجربه ھل ھي افضل للمريض ؟ولماذا؟
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ميرخان : في البدايه من تأسيس ھذه العيادات كان المريض يدفع فقط ٠٥٪من السعر والباقي الدولة تدفعه أو تسديده للصيدلي اي ٠٥ 
٪ من السعر الاجمالي للوصفه  والصيدلي ياخذ فقط ٢١ ٪من سعر الشراء والحكومة تدفع ٠٥٪ من سعر الوصفه الخدمات محدودة 
 والربح محدود بينما في الصيدليات الخاصه ٥٢٪_٠٣٪ او اكثر الربح للصيدلي . 
 ااشواق : كونك صيدلي قطاع خاص في البدايه ھل كان من اختيارك الخاص ان تتحول الى ھذا النوع من الصيدليات ؟ ولماذا؟ 
 انقطع الاتصال ايضا مع المشترك  وحاولنا اجراء اتصال اخر ! 
 اشواق : اعتذر لانقطاع والخلل الفني  نرجع نكمل 
 صف لي عملية تسعير الادويه بالعيادات الاستشاريه اللي شبه حكوميه 
ميرخان : لازم نميز بين ھذه الاستشاريات والاستشاريات الحكوميه او شبه الحكوميه اقصد ، أساسا الصيدلي يجھز الصيدليه 
بالادويه من المذاخر الأھلية حسب احتياجات الصرف بكل عياده استشارية لانھا محدده بالصرف فقط لمراجعي العّياده الاستشارية 
فقط في عدھم نضام بدائي كمبيوتري توثق به قوائم الادويه من المذاخر بأسعار الشراء من المذخر تحدد الأرباح منھا  ٢١٪ 
للصيدلي وتوثق سعر الوصفه الكلي وليس الجزئي بضربھا ب ٢١٪ تضاف والسعر الاجمالي الوصفه يتم تقريبه لأقرب عمله لكل 
 الوصفه وليس لكل ماده  . 
 اشواق : ممكن تذكر النسبه التي تدفعھا الدولة من سعر الوصفه الى الصيدلي وھل تلتزم دائما ًبالدفع ؟
ميرخان : في الضروف الحاليه لا لان انا كنت ايضا ضد ھذه الفكره وفعلا حصلت مشاكل وتم التوقف عن ھذا لمنع استغلال 
المريض والطبيب لھذا السبب  فتقريبا الغيت النسبه في بدايه الشھر الثالث في العام الحالي ٤١٠٢ صار المراجع ملزم بالدفع كامل 
لسعر الوصفه وبقت نسبة أرباح الصيدلي ثابته السبب في إلغائھا او توقفھا ھو إساءة استخدامھا من قبل كل من الطبيب والمريض 
مما أدى الى ھدر بالأموال وبنفس الوقت ھدر بالادويه لان المريض احيانا يفرض على الطبيب كتابة وصرف بعض الادويه التي قد 
تكلف الدولة وھو أصلا لا  يحتاجھا او يتم المتاجرة بيھا في السوق السوداء او مكانات اخرى وھذا طبعا بسبب الحاجه المادية 
 احيانا .
  ?  em rof erom nialpxE ? natsidruK ni scinilc tnatlusnoc eht ebircsed uoy naCاشواق: 
ميرخان : ھي عيادات انشأتھا  وزارة الصحه في كردستان تختلف عن العيادات الخاصه اما بالنسبة لنا ھي شبه خاصه فاجورھا 
مخفظه عموما الطبيب والأشعة والمختبر الطبيب له راتب من الحكومه اضافه الى نسبة ٠٠٠٣ دينار عراقي لكل وصفه اما 
الصيدلي فليس له راتب من الدولة في ھذه العيادات لكن له ربح محدود في سعر الوصفه الاجمالي وھو ٢١ ٪ مسؤوليته ھي توفير 
 الادويه المطلوبة لمراجعين العّياده الاستشاريه وبيعھا بأسعار اقل من الأسعار في الصيدليات الخاصه في القطاع الخاص . 
 اشواق :ھل ھو اختياري للصيدلي للعمل في ھذا المجال ؟ 
ميرخان : ھو اختياري الالتحاق بھكذا  صيدليه وكان اختياري انا لان السوق والقطاع الخاص وتعاملاته مليت منه فحبيت أغير 
 أضافه الى انه بيه فائده للناس والمراجع خصوصا .
 اشواق : شنو اللي خلاك تمل من السوق وتعاملاته ؟ 
 ميرخان : المھنية قلت من العمل الصيدلاني ھذا سبب رئيسي لتركي العمل ھناك 
  ? metsys gnicirp lacituecamrahp siht morf ton seod ohw dna tifeneb ohwاشواق 
ميرخان : الدخلاء ھم المستفادين الرئيسيين لان معظم الصيادله باعوا إجازاتھم الدخلاء اصحاب رؤوس الأموال والصيدلاني تراجع 
 وصارت المھنه  تفتقر للعلميه .
 اشواق :ممكن تعرف من ھم الدخلاء وماذا تقصد بالدخلاء ؟ 
 ميرخان : الدخيل ھو صاحب راس المال الذي يشتري شھادة الصيدلاني ويفتح الصيدليه بھا  
 الصيدلاني غير مستفيد من شھادته ويأخذ راتب محدود وخلص 
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  ? ti tuoba erom nialpxe uoy naC ? bboj ytrid eht tuoba tahwاشواق : 
ميرخان: ھي إغراء الأطباء  لكتابة الوصفات وترويج المنتجات مثلا بسفرات خارج العراق او ھدايا مثل ثلاجة او لأب توب فيتم 
صرف كثير من المنتجات لھذه الشركات وان كان المراجع لا يحتاجھا في الوصفه ولا يوجد شيء يحمي المريض من ھذا الشي الذي 
 فيه ھدر لصحته وأمواله أكيد 
 اشواق : وأين الرقابة الدوائيه  ونقابة الصيادله ووزارة الصحه ؟ 
ميرخان :موجوده جميعا لكن ليس لھا دور فاعل فالنقابه تنتضر الانتخاب فقط ولا تستطيع اثارة الخلافات برأيي يجب ان  توجد جھه 
عادله ثالثه ھي الّتي تحاسب بحياديه لتكون عادله وحازمه في المحاسبة . الدور المطلوب لھذه الجھات غير موجود القانون يحتوي 
 الكثير لكن لا يوجد له تطبيق وتنفيذ في أرض الواقع .القانون في العراق الان يطبق فقط على الضعيف ولا يطبق على القوي .
 eb dluoc metsys gnicirp lacituecamrahp eht kniht u od tsicamrahp a sa dnetxe tahw oTاشواق : 
  ?dohtem tseb eht si tahW ? erutuf ni degnahc
 dog nggميرخان: َھَذا يعتمد على وضع البلد ككل لآنني دخلت في برنامج ضمن نضام منضمة الصحه العالمية اسمه  
 اللي ھو برنامج يھتم ويبدأ بالدواء من الصناعة الى القوانين وتقيمه في البلد لكي توافق المواصفات nicidem fo ecnemevog
العالمية لكن مع الأسف نحن لم نطبقه في العراق لكن الدول العربيه كلھا طبقته  بعدھا  انقطعت لان لم نجد تعاون من البدايه في 
الاصلاح ... سوء أوضاع البلد وسوء الاداره كلھا أسباب لذلك وأي تغير ممكن يحصل لكن ليس بسھوله لانه بعد احداث ٠٩٩١ 
كلشي تدھور ومنھا مجال الصيدله كأي مجال اخر بالبلد تم تدميره تدريجيا للأسف من ٠٩٩١ كلشي بده يسوء اما إصلاحه العمليه 
ينرادلھه بخت ھھھھه.ووقت قد أكون متشائم والقانون ھو الحاكم وكل القوانين موجوده للتنظيم وھي أساسا قوانين رصينة لكن التنفيذ 
 غير رصين .
 siht ni s lacituecamrahp gO ytilibaliava eht tuoba tahwاشواق: النضام في الاستشاريات جيد للمريض لكن 
  ? kniht uoy od tahW ? tahw ro retteb ro rotces cilbup eh t ot ralimis ti sI ? ? scinilc epyt
ميرخان : يعتمد ھذا الشي على الأطباء الاستشاريين العاملين في ھذه العيادات وتخصصاتھم وانا كصيدلي ملزم التوفير الادويه التي 
تدخل بضمن اختصاصات العّياده التي اعمل فيھا اما ان أكون فري مئه بالمئة لآني محدد بالعياده فقط وضمن صيدليه محدودة 
محصور في بنايه مع مراعاة السعر لازم تكون كوست ايفيكتف وتكون مناسبة بالسعر والنوعية بمعنى اخر  يكون اللجينيريك اكثر 
رغم كونه مطلوب احيانا من قبل المريض وخصوصا أن مراجعين ھذه العيادات كانوا  مستفيدين من النسبه المخفظه بالسعر للوصفه 
٠٥٪ ولكن حصلت في بعض المحافظات أسائه لاستخدام ھذا النظام و للوصفه وتحريرھا فيكون عبيء للوزاره بغياب 
 وانا كنت من المعارضين لنضام دعم الوصفه لخمسين بالمئة لانھا تفتح باب لاسائة الاستخدام لتحرير الوصفات من serussaer
قبل بعض الأطباء او بيع العلاج من قبل بعض المراجعين المزيفين وانا أوفر الدواء الذي يكون مجاز من وزارة الصحه وأمين 
ومسجل  مع مراعاة السعر .فقد كتبت للسيد الوزيرشخصيا حول موضوع إلغائھا   لانه ومن خلال تجربتنا وجدنا ان  فيھا ضرر 
لكل العمليه مما يشكل عبيء .فمثلا انا اطلب الحكومه اقصد وزارة الصحه ٠٢ الف دولار لم يتم تسديدھا لي لحد الان وھذه واحده 
من المشاكل ومتعلقات ھذا النضام والنسبه التي تم تحديدھا والمراجع يدفع ٠٥٪ والصيدلي الدولة تدفع له ٠٥ ٪ من سعر شراء 
 الدواء مما قد يؤدي إرباك لي انا كصيدلي وضرر مادي .
اشواق : بالنسبة للعقود التي تم إبرامھا بينكم وبين وزارة الصحه او إدارة ھذه العيادات ، ما ھو مدى دقة تنفيذ ھذه العقود والتزام 
 الطرف الاخر بيھا ) وزارة الصحه(؟ھل انت ضامن ؟ ھل انت محمي لحماية حقك ؟ 
ميرخان: لا و^ حاليا ماضامن خصوصا بعد الضروف الحاليه . في البدايه كان كل شھر نستلم نقودنا لكن الان الوضع اختلف . 
المستحقات كان شھريا نأخذه لكن نضام بنكي غير موجود في ھذه العيادات لكن في محايدين وتوثيق وتقرير شھري وتدقيق 
 بالحسابات وتخضع للتدقيق وعليه يصير الدفع . 
 اشواق : المشترك لم يكن لديه وقت لقرائه الملف المرفق عن الدول الاسكندنافيه 
  في دول الشمال وحاولت أوضح باختصار معنى النظام التعويضي tnemsrubmierأعطيته نبذه مختصره عن نضام ال 
  . وتبين لي انه لديه اطلاع مسبق عن بعض الأنظمة في بعض الدول الأوربية مشابه نوعا ما وسألته tnemsrubmier
 ?qari rof yllufesu eb  ti fo stnemele emos dluocاشواق: 
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ميرخان:اعتقد انه في الدول المستقرة  ھو الأفضل لانه لا يحصل فيھا سوء استخدام لكن وضعنا بالعراق يختلف لانھا قرارات سيادية 
 نحن كان قد  اقترحنا ھذا النضام والوزاره وافقت عليه لكن صار سوء استخدام لھذا النضام 
  seirtnuoc rehto morf nrael ot elba eb tsum rekam noissedالاستقرار في النضام وقوانين 
 tnemsrubmierاشواق : العراق بلد فيه المواطن مستھلك لايوجد دعم لميزانية الادويه وأكيد نضام تركيا كان شيء والآن ھو 
وتم عرضه على الجھات المسؤله  لتطبيقه ھنا لكن لم تكن استجابه الوضع السياسي والسياسه العامه ما تساعد لحصول تغير الا في 
 حال حصول تغير جذري البيت اللي يصير بيه ھكذا نوع من المرض العائله كلھا تتدمر 
  ? aedi siht ot tcaer dluow srotca tnereffid kniht u od wohاشواق: 
 بعض الأطباء moc ni elbisivniميرخان : أكيد يكون في صالح المريض مثلا الطبيب راح يخسر دخل غير مرئي مع الأسف 
يفضل مصلحته على مصلحة مريضه يحتاج ان يكون ھناك  نضام يضبط التطبيق  ومن أمن العقاب أساء الأدب وانا لا أقول الكل 
ھيجي سيئين الكل لازم يلتزم في ھذا الحال صعب لان حاليا الضروف كله تغيرت النفسيات ايضا تغيرت اما الصيدلي العراقي 
لايؤمن بالنضام المصرفي البنكي يعني الصيدلي ما يثق بالبنك ھنا ھسه كل واحد يريد نقوده عنده في بيته لان البنوك في العراق 
تنقصھا الثقه بين النضام المصرفي العراقي ھي صفر كثير من الناس نقودھا كانت بالمصارف فجأه ضاع كل شئ وكل شي راح 
بسبب ان المصارف كانت بيد السلطة الحاكمه وتم سرقة الأموال. ف الصيدلي سوف تكون عنده مشكلة التعامل المصرفي والتسديد 
من قبل الدولة. وبكلمات اخرى ان ھناك مشكلة ثقه كبيره بين البنوك والفرد واعني الصيدلي وكذلك الوضع السياسي الغير مستقر 
 للدولة حاليا 
 ? tneitap eht fo noitcaer eht tuoba tahwاشواق : 
ميرخان في كردستان المراجع متعود ياخذ ادويته مجانيه في القطاع العام وبعد ذلك  في القطاع الخاص وكذلك شبه الخاص المراجع 
بالعكس يستفاد لذلك الان الإقبال كثير على ھذه العيادات الاستشاريه وخصوصا من كانت خمسين بالمئة لكن في من أساء استخدام 
 ھذا النضام فتم إلغائھا بالعكس المريض راح تخدمه ويرتاح اكثر اذا لم يسيء لاستخدام  وفي حال وجود تحديد لقوانين 
 اشواق : ھل حصل التوقف عن دفع خمسين بالمئة من سعر الوصفه بعد ام قبل االازمه الحاليه بالعراق ؟ 
ميرخان : حصل قبل االازمه خصوصا بعد ان توقف الحكومه ألمركزيه من دفع المستحقات المالية لكردستان اقصد الميزانية مما 
 أدى ايضا الى تقصير في دفع المستحقات للعيادات الاستشاريه وغيرھا 
 ما ضلت مصادر وحصل عجز بالميزانية 
 ni hom ot gnidrocca natsidruK ni snoitacidem nmO tceffe sisirc eht tuoba tahwاشواق : 
  ? OHW ot natsidruK
  او ينفقد egatrohsميرخان : النقص اكثر شي صار في القطاع العام الذي ھو أساسا موجود قبلھا بسبب كيماديا الأكثرية يصير 
بسبب انه بعض الدول لا تسمح  بدخول الادويه لمنطقة العراق مثلا المخدرات من يصير قصور المريض يعاني ومن نحصلھه تكون 
. وكذلك ادوية المزمنه والسرطانيه لكن الإنسولين السنه وضعه جيد في كردستان لكن الادويه السرطاني ھمھمله deen rednu
 وخصوصا الأشياء ألمساعده لمريض السرطان لكن من جه اخرى تكديس مواد اخرى مثل egatrohs gib smeti lativ
. حاليا ytilibaliava  في دھوك صار الضغط اكثر مما اثر على ecnatsiserالمضادات الحيويه بشكل عالي مما يؤدي الى زيادة 
 ل ٠٩٪   وكلھم محتاجين  ادويه  وحالتھم noitalupopبسبب اللاجئين الذين  زاد عددھم بالفتره الاخيره مما سبب زياده في ال 
 تعيسه  مما اثر على كمية الادويه في المحافظة بشكل عام .  
  ? dda ot tnaw u erom kniht ynaاشواق : 
 كثير من egatrohsميرخان : نحن نستلم   منح ومساعدات من منضمات عالميه مختلفه لكن ليس بالكميه التي تغطي كل 
   ويأخذون بآراء المؤسسات واحتياجه dezinagroالمنضمات  بدو يكونون اكثر 
  tol a sknahtاشواق : 
 daPi nim arf tdneS
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------------------------------------------------------------------------------------------------------------ 
At the beginning of the interview I tried to mention some points of common despite 
the weak internet and sound, but the recording started and the interview by mention 
these points:  
1. The interview will be muffled 
 2. Brief introduction of explained search and rename it and pharmaceutical pricing 
system in Scandinavia  
3. Illustrate that the corresponding language choice language Arabic-English-
Norwegian 
 4-dialogue will be free 
5-It could be a technical fault happened, so we can just retry the connection! 
The participant was busy and he answered the telephone, because he was in his 
office .He is the Manager of the Pharmacy Department in the Ministry of health in 
Kurdistan  
AS: Can you introduce yourself please? 
K : I am pharmacist K, Director of Department of pharmacy in […] and health 
department I worked in WHO( in the past but not now).I own my pharmacy and I 
manage the process within the Advisory clinic(consultation clinics in 
Kurdistan ).Before that I had my own community pharmacy in private sector, then ,I 
turned to consulting clinics in which there is a limited margins and prices .There’s a 
limitation for the pharmacist margins in not more than 12% only .In addition to that 
this type clinics give low cost  for all services (such as laboratory or x-ray services) 
provided to patients and the patients pay low wages for the services. 
 AS: Please, describe how the prices of pharmaceutical decided in this type 
pharmacy in these clinics? In other words, how is the price of medicines in this type 
of pharmacies decided?  
 K: At the beginning I will give  an introduction about this type clinics in Kurdistan ,I 
called it a semiprivate clinics but not completely private because its managed and 
financed by the Government .I have reviews on this type pharmaceutical pricing 
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system because the patients misuse  that doctors in this clinics to get medications. 
Both in Iraq and Kurdistan ,the existence of the pharmaceutical companies which 
have focusing on advertisements for products ... Despite of they  are good clinics  in 
services ,good locations and modern buildings, furniture and equipment’s, but 
exploitation of the patients due to the misuse of the medical system 
 AS: Disconnected and started a new connection! 
AS: But why you feel uncomfortable toward this system (50% reimbursement for the 
prescription price) ?Is the experience best for the patients? And why? 
 K: At the beginning, the clinic’s patients must only pay 50% of prescription price and 
the rest of prescription cost will the government pay. The process occur by repaid to 
the pharmacist 50% of the total price for the prescription and the pharmacist takes 
only 12%margin of purchase price and the Government pays 50% of the price of 
prescription services are limited to the patients of clinics only with limitation in prices 
and margins while in private pharmacies, there are about  25% _ 30% or more 
margins to the pharmacist.  
 AS: As a pharmacist in private sector at the beginning of your life and your 
pharmaceutical work, was the choice to turn into this kind of pharmacy optional? And 
why?  
AS: Contact was lost again and I tried to make another connection!  
 AS: I apologize for the interruption and technical bugs, and I will go continue to my 
questions about the pharmaceutical pricing system in this type pharmacy, please 
describe, how the pricing process managed by government in this semi private clinics 
(consultation clinics)? 
 K: Its necessary to distinguish between these clinics which are a semi-governmental 
(semi private) and the other clinics which are full governmental (public), basically the 
pharmacist equipped the pharmaceuticals which are essential in this clinics by the 
private wholesales according to the need of this clinics which depend on the type of 
the consultation for different physicians, in addition to the limitation of the patients of 
clinics only. The clinic have a primitive computer system documenting and the 
registration of the prescriptions happened daily, the drug lists of purchase prices of 
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the wholesale and adding 12% to the wholesale purchase price of the total price of 
prescription as a limited margin  to the pharmacist in this pharmacy ,some time we 
must take the nearest to the rounded price in the Iraqi market; example if the total 
price of a prescription to one patient is 150 ID ,so the patient will pay 250 ID(the 
lowest value (bank)note is 250 ID),because 150 ID have no value in Iraqi market and 
so on.  
AS: Describe the reimbursed percentage which pays by the government to the 
pharmacist? Do they pay always at the right time?  
 K: In the current circumstances because I was also against the idea and really got 
problems and stop this to prevent exploitation of the patients and the doctor for this 
reason virtually abolished in Mars  2014.After this date , the patients  must  pay full 
price for prescription but  pharmacist  margins are still the same (12% only ). The 
reason to stop this type reimbursement was the abuse by both doctors and patients, 
resulting in wasted money and wasted medicines because the patient sometimes 
forces the doctor to write some pharmaceuticals that may cost the government 
(Ministry of health) but its originally not needed or omitted or some people is traded 
on the black market or other places and this of course, because of need and 
poorness. 
 AS: Can you describe the consultant clinics in Kurdistan? Explain more for me? 
 K: They are clinics established by the Ministry of health in Kurdistan, and they differ 
from private clinics. For us are semi-private, wages generally are low. Their staffs are 
physicians, radiologist and laboratory. Doctors get salaries from the Government in 
addition to 3,000 ID (Iraqi Dinar) for each prescription .The pharmacist get no salary 
from the State in these clinics but has won limited in the total recipe and fixed rate is 
12%.The pharmacist responsibility is the provision of medicines required for advisory 
clinic (consultation clinics) and patients sold at lower prices than prices in private 
pharmacies in the private sector. 
  AS: Is that an optional to the pharmacist for work in this area? 
  K: It is an optional job to work in this type of pharmacy , I was completely my choice 
to change my job to this type clinic because of that I was boring from the private 
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pharmaceutical market and at the same time ,because I think that this type clinics 
have benefit to help people (poor people). 
AS: Why are you so tiered (boring) of pharmaceuticals marketing in private 
pharmacies? 
  K: The most important reason to that for me was absence of the professional 
identity and work to the community pharmacy in Iraq now. (He said that with painfully 
clear words). 
AS: who does benefit and who does not benefit from pharmaceutical pricing system 
now?   
K: I think the intruders have the most benefit of this non organised pricing system in 
Iraq. Many pharmacists have sold their profession license to the intruder’s capitalists 
and pharmaceutical review and became a profession lacks scientific view. 
 AS: What do you mean by intruders? Can you define “intruders “/Explain, please? 
  K: The intruder is the owner of the capital who buys the pharmacist profession and 
the pharmaceuticals and non-pharmaceutical and has complete capital to finance the 
community pharmacy .The pharmacist role in the community pharmacy as an 
employer with a limited salary per month. 
AS: The dirty job? Can you explain more about it?  
 K: Most of the pharmaceuticals companies try to lure the doctors to write 
prescriptions, product promotion, by giving them for example, travels outside Iraq or 
gifts such as a refrigerator or laptops. The doctors help to sale many of products of 
these companies and even if the patient was not required on recipe and nothing 
protect the patient from these thing that was a waste of their money and uncertain 
treatment. 
 AS: Where are pharmaceutical control, pharmaceutical association and the Ministry 
of health? 
K: All are founded but they don’t have an active role, the pharmacy syndicate is 
waiting for the election only and will not make problems and conflict . In my opinion, 
there must be a fair third-party is held in neutral to be fair and firm in accounting. The 
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role required for the non-existent law contains a lot but has no application and 
implementation on the ground. The law in Iraq now applies only to the weak and not 
strong persons. 
 AS: To what extend as a pharmacist do you think the pharmaceutical pricing system 
could be changed in future? What is the best method? 
 K: This depends on the development of the country and its political situations as a 
whole. In the near past ,I worked with WHO as a part of an international 
pharmaceutical program to develop the pharmaceutical system generally in 
Iraq .Program name is GGM (Good Governance of Medicine) because It was 
interested to me and its consider the medication from the industry to the country's 
laws and to approve international standards but unfortunately we could not use it in 
Iraq because of the corruption, but its  then applied successfully by the other 
neighbouring Arabic states. After that I cut off with this because we found no 
cooperation from the governments in addition to the poor conditions in the country 
and poor management are all reasons for this .Any change possible but not easily to 
get it. Especially after the events of 1990’s deterioration, including pharmacy as any 
other area of the country destroyed and the process of repairing need time and luck (I 
think. Said that laughing). I’m may be pessimistic about that but the ruling law and all 
laws exist and are basically solid laws but implementation is not sober. 
 AS: What about the pharmaceutical availability on this type of clinics ? Is it similar to 
the public sector or better or what? What do you think? 
  K: this thing depends on consultant physicians working in these clinics, specialty 
and I (as a pharmacist) is obliged to save drugs that fall within the competence of the 
clinic where I don’t used to have every think in my pharmacy  because my pharmacy 
users are restricted only  within the clinic , with taking in consideration  suitable price, 
its  necessary to be coast effective price and be suitable for price and quality, in other 
words be more suitable to the patients of clinic ability have mostly the generics but 
sometimes the original drug is  required by the patients at this time I can order it for 
him .In addition to the low cost of services specially when it was 50% of the whole 
prescription price only must paid , but in some provinces in Kurdistan ,there was a 
misuse for this system and the recipe editing is mobilized because of the absence of 
reassures and the good control system. I was opponent to assert supports recipe to 
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50% because it opens for the abuse to edit recipes by some doctors or by selling 
treatment by some patients/or the clinic users and the fake recipes of the fake 
patients. As a pharmacist in this clinic ,I’m oblige to buy just the pharmaceuticals 
which are approved by the Ministry of health and have register control documents 
taking in consideration the price and its affordability to the users of this clinic. I had 
written to Minister of health in Kurdistan for the cancellation of this type support 
(50%) and the patients pay now 100% of the total price. From our experience we 
have found that the damage to the whole process is mobilized. In addition to that ,this 
system was difficult to me as a private pharmacist and made many economics 
problems to me because of the payment of the recipe cost (50% from patient and 
50% from the State «ministry of Health). For example, the government «the Ministry 
of health “have not paid to me more than 20,000 USA dollars til now from mars , so 
this type problems can cause confusion for me as a pharmacist and economic 
damage damage. 
AS: About the  contracts concluded between you and the Ministry of health or the 
management of these clinics. What about the accuracy of these contracts and the 
obligation of the other party omitted (MOH)? Are you a guarantor? Are you protected 
to protect your rights?  
 K:I have no guaranty and no complete protection, specially after the current 
circumstances and Iraq crisis. Initially, each month we receive our money but now the 
situation differed. Receivables was a month we take but the banking system is not in 
these clinics but the clinics have employers who have the responsibility for the 
documentation process and reporting monthly and checking accounts and the 
dispensing process in the pharmacy to make it more the process more payable.  
 AS: the informant did not have time to read the attached file about the Nordic 
countries gave brief assert the reimbursement in Nordic tried to explained briefly the 
meaning of reimbursement system . And I found out that he had informed in advance 
about some systems in some European countries somewhat and I asked him this 
question: 
 AS: What do you think as a pharmacist ,could some elements of Nordic 
reimbursement system  be useful for Iraq? 
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K: I think it is best for stable countries which have technical control to avoid system 
abuse. But we have Iraq!, and its is different because we were sovereign decisions. 
We suggested and proposed a similar to this system and the Ministry approved in 
this clinics but the misuse of this system stopped it. The stability in orders and laws 
can help the decision maker to learn from other countries experiment ,but now is 
difficult because of the political situation. I think Iraq now is a consumer country who 
does not have support for the budget and certainly assert for its economy .We tried to 
take or try the Turkey reimbursement system  and asked to applying it here but not 
response. Political status and policy help to change unless radical change “House 
which have this problem ,so the whole family be destroyed” 
AS: how do you think different actors would react to this idea? 
 K:I’m  sure ,it will be good and interested for the patients, but not for the 
doctors(physicians)because of that they will lose a type of nonvisible income but not 
all doctors 8most of them. Some doctors prefer to get complet benefit of the patient. 
We need first a good and strong system to regulate the application of such type 
system. I’m not saying that all are bad ,but now ,every think is difficult and the 
personality is changed and many circumstances can affect the process of application 
of any new system in Iraq. While the Iraqi pharmacist dosnt believe in the Iraqi banks 
and there is a confidence problem between them because of the instability of the 
governments ,every pharmacist now will have his money in his owen pocketmoney 
home not in the bank, because of that banks in Iraq lacked confidence between the 
Iraqi banking system and people. Many people put their money in the banks 
suddenly lost everything and everything was because of the political situation was 
bad , however, the ruling authority and has been stealing money. The pharmacist will 
have the problem of banking and payment by the State. In other words, there is a 
problem of trust between banks and individual and I mean pharmacist as well as the 
political situation instability. 
 AS: What about the reaction of the patient? 
  K:In Kurdistan ,patients used to take his medication free of charge in the public 
sector, full of charge in private sector and as well as in semi-private pharmacy , 
patients versa paid 50% of charge at the beginning and it was good experiment for 
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him and it was acceptable and comfortable idea for him ,but the abuse terminate this 
experiment .So ,I think if we can have good control sytem to regulate this process ,it 
will be perfect to Iraqi patients specially the poor one who need expensive 
medications. 
AS: When the system had stopped paying with 50% of the price of the prescription? 
Was that after or before the current crisis in Iraq?  
 K:It stopped before the crisis, especially after the Central Government stopped 
paying dues to Kurdistan. I mean the budget and that also led to default in payment 
for consulting clinics and other primary sources of public and semiprivate clinics and 
this affect directly on the health care system budget also. 
 AS: what about the crisis effect on medications in Kurdistan according to ministry of 
health in Kurdistan to WHO?  
 K: The shortage of pharmaceuticals mostly became in the public sector institutions 
which is basically exist before the crisis, because they depend in majority on 
KIMADIA (  ) .The shortage happened because some States do not allow the entry of 
medicines to Iraq, for example analgesic drugs, the drug area becomes insufficient 
for patients and when we get it, so they were under the country need. As well as 
chronic and cancer drugs but in this year it was a good availability of insulin  in 
Kurdistan but the cancer drugs were neglected and under need and some items  
become weary for cancer patent specially the vital items and big shortage in things 
which help cancer patient. On the other hand the accumulation of other materials 
such as antibiotics which is couse increasing in resistance. After crisis  in the 
pressure became too much impact on availability of medications because of the 
dramatically increase in the number of of refugees .This immigration process led to 
increase in 90% of the population in my city and this led to similar increase in the 
pharmaceutical need in this area. The most of refugees need vital medication and 
they are in bad condition. All that were strongly affect the availability of medication 
generally in all Kurdistan area. 
 AS: Any thin more you want to add about this?  
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 K: We receive grants from various global organizations but not in the quantity that 
covers every shortage. Many organizations appear to be more organized and take 
the views of the institutions and the real need. 
 AS: Thanks a lot 
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Appendix  5. PDF /documents to the diabetes data  
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Appendix  6. NSD approval appliance document  
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Appendix 7. Executive Summary about the Nordic countries- 
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Executive Summary about the Nordic countries  
 
Figure 1.The Nordic countries are situated in the northern part of Europe. 
The Nordic countries refer to the following countries: Norway, Sweden, Denmark, 
Finland and Iceland. The share a common well-fare ideology and the Nordic health 
care model is based on a principle of free and equal access for all citizens. In the 
summary the focus is on Norway ,which is described in detail, and brief summaries 
are given on the other countries. 
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(http://en.wikipedia.org/wiki/File:Share_of_total_population_in_the_Nordic_countries_
in_2013.JPG, 2013) 
Figure 2.Shre of total population in the Nordic countries from 2013. 
1. Norway 
The figure illustrates a chart for pharmaceutical system in Norway. Thereafter the 
system is described in more detail. 
Figure.3 A chart for pharmaceutical system in Norway (se web link below) 
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Source:Whttp://whocc.goeg.at/Downloads/Conference2011/PraesentationenPPRIKo
nferenz/general_PPRI%20conference%202011%20Country%20poster%20book.pdf  
(http://whocc.goeg.at/Downloads/Conference2011/PraesentationenPPRIKonferenz/g
eneral_PPRI%20conference%202011%20Country%20poster%20book.pdf, 2011)  . 
 
The health care system  
The principle of equality in health, both social and geographical, is central when it 
comes to forming Norwegian health policy. The Norwegian health care system is 
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founded on the principles of universal access, decentralisation and free choice of 
provider. It is financed by taxation, together with income-related employee and 
employer contributions and out-of-pocket payments (co-payments). All residents are 
covered by the National Insurance Scheme (Folketrygden, NIS), managed by the 
Norwegian Health Economics Administration (Helseøkonomiforvaltningen, HELFO). 
Private medical insurance is limited. While health care policy is controlled centrally, 
responsibility for the provision of health care is decentralised. Local authorities at 
municipal level organise and finance primary health care services according to local 
demand. The central Government has overall managerial and financial responsibility 
for the hospital sector. Norway’s four regional health authorities control the provision 
of specialised health services by 27 health enterprises. 
The pharmaceutical system 
The Ministry of Health and Care Services (Helse- og omsorgsdepartementet, HOD) is 
the legislative authority. The Norwegian Medicines Agency (Statens legemiddelverk, 
NoMA) (subordinate to the HOD) is in charge of market authorisation, classification, 
vigilance, pricing, reimbursement and providing information on pharmaceuticals to 
prescribers and the public. HELFO decides on reimbursement for individual patients 
for pharmaceuticals not included in the general pharmaceutical reimbursement or 
indications not covered by general reimbursement. HELFO also monitors the 
prescriptions issued by outpatient doctors. 
All major international pharmaceutical companies are represented by marketing’s 
office in Norway, but only very few of them have established their own manufacturing 
units in the country. In Norway there are three wholesalers providing a full range of 
products to the market, belonging to the leading European pharmaceutical 
distribution companies: 
• Norsk Medisinaldepot (NMD), owned by Celesio AG , with a market share of 
47,6 %; 
• Apotek 1  AS, owned by Tamro OYJ, with a market share of 28,9 %; 
• Boots Norge AS, owned by Alliance Boots Plc with a market share of 23,7 %. 
Each of the wholesalers is vertically integrated with their own pharmacy chain. 
• Only community and hospital pharmacies are allowed to dispense prescription 
medicines. Of the 674 pharmacies there are 33 public hospital pharmacies. There are 
approximately 7,300 inhabitants per pharmacy (4.9 Mio. inhabitants). In addition 
pharmaceuticals are dispensed by small outlets belonging to the pharmacies. 
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Grocery stores, gasoline stations e.g. are allowed to distribute a restricted list of over-
the -counter. 
 Pricing 
The Norwegian Medicines Agency (NoMA) is responsible for setting maximum 
pharmacy purchase prices . All suppliers of prescription pharmaceuticals must apply 
for a maximum price, whether or not they are seeking reimbursement for the product. 
Pharmaceuticals can only be sold at or below the maximum price level.   An 
international price referencing system has been used since July 2002 to set 
maximum prices for both new and existing pharmaceuticals. Prices are based on the 
average of the three lowest pharmacy purchasing prices in Austria, Belgium, 
Denmark, Finland, Germany, Ireland, the Netherlands, Sweden and the United 
Kingdom. If a pharmaceutical is marketed in fewer than three of the reference 
countries, the mean price is taken of the countries where a market price exists. 
Because pack sizes in different countries are not always directly comparable, price 
comparisons are made on the basis of units, e.g. price per tablet/dose. Local 
currency prices must be converted into Norwegian currency NOK, using the mean 
exchange rate of the last six whole months, as presented by the Bank of Norway. 
Wholesalers are free to negotiate mark-ups with manufacturers because the NoMA 
sets prices at the pharmacy purchasing price level. Mark-ups for generics and over-
the-counter products are significantly higher than for branded pharmaceuticals. 
Pharmacy mark-ups for prescription products (both reimbursed and non-reimbursed) 
are fixed at 7% for pharmaceuticals with a pharmacy purchasing price (PPP) up to 
NOK 200 / € 25.5, and at 4% of the price above NOK 200 / € 25.5. There is also a flat 
rate add-on of NOK 22.00 / € 2.8 per pack, plus value-added tax (VAT) (25%). An 
additional flat rate add-on of NOK 10 / € 1.3 is applied to addictive products (narcotic 
and psychotropic substances). Mark-ups on OTC are not regulated. 
Generic prices cannot exceed the maximum market price of the original branded 
product. A price model called the stepped price model (Trinnprismodellen) came into 
effect in January 2005. Under this scheme, a maximum reimbursement price is set 
for affected pharmaceuticals (both branded and generics). The maximum 
reimbursement price level is automatically reduced in stages (steps) following patent 
expiry. The size of the price cuts depends on annual sales prior to the establishment 
of generics competition and time since competition was established. 
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 Reimbursement 
Reimbursement decisions are made by the Norwegian Medicines Agency (NoMA). 
The pharmaceutical companies need to follow the Norwegian guidelines for pharma 
economic evaluations when applying for reimbursement. 
Generally speaking the Norwegian reimbursement system may be characterised as 
disease and consumption based. Whether a pharmaceutical is reimbursed and the 
amount of reimbursement depends on the following criteria: 
• The illness must be considered serious and chronic, for which long-term medication 
(more than three months per year) is necessary; 
• The annual consumption and cost for the patient (no co-payment above an annual 
ceiling of NOK 2,105 / € 257,40; in 2014 ;card scheme uses. This card covers 
approved user fees for pharmaceuticals and for treatment by a doctor, a 
psychologist, in outpatient clinics and x-ray institutes. 
• Low income pensioners and children under 16 are exempt from co-payment. 
Pharmaceuticals are grouped into four reimbursement categories (Schedule 
numbering is depending on law paragraphed which mean §2,§3a,§3b and §4. 
Number one is not relevant and not mentioned) 
• Schedule 2 (§2): General reimbursement• Schedule 3a and 3b(§3a and §3b): 
Reimbursement on a named patient basis. Reimbursement is granted upon 
submission of an individual patient application. 
• Schedule 4(§4): Reimbursement of pharmaceuticals used to treat serious 
contagious diseases such as tuberculosis, syphilis or HIV/AIDS.100% 
reimbursement. 
The standard patient co-payment for reimbursed pharmaceuticals is 38% up to the 
annual ceiling (see above). All expenses above this threshold are covered by the 
National Insurance Scheme. The annual limit also includes co-payments for 
physician consultations, laboratory tests, radiography, etc. 
Inpatient pharmaceuticals are covered by the public hospitals. In Norway, hospital 
pharmaceuticals are covered by the hospital budget. There are pharmaceutical and 
therapeutic committees established by the hospitals which set up and decide on 
inclusion of medicines to the hospital pharmaceutical formulary for internal use. No 
countrywide medicines lists for in-patient care exist (for more information see: 
(http://whocc.goeg.at/Publications/CountryReports, 2014). 
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The other Nordic countries 
The healthcare systems for the other Nordic countries are in principle similar to the 
Norwegian one, with minor differences that in the following are described country by 
country 
2. Swedish  
In Sweden ,pricing and reimbursement decision on pharmaceuticals is decided by 
Swedish national authorities. The Medical product agency (Läkemedelsverket, MPA) 
and the Pharmaceutical Benefit Board (Läkemedelsförmånsnämnden, LFN). They do 
not use the  International reference pricing but their descion are rather based on 
health economic evaluations. 
Pharmacies in Sweden  
For almost four decades, Sweden was one of few countries in the world with a 
government run monopoly of pharmacies, banning private retail (pharmacist 
ownership pr pharmacy chains) of pharmaceuticals. When a new centre-right 
government was elected in 2006, one of its promises was to abolish the monopoly 
and sell of most of the state-owned pharmacies. This plan was put into action in 
2009. Private competition was allowed in late 2009, and a majority of the 
government-owned pharmacies were rebranded during January and February 2010 
as they were transferred to new owners. The newly privatized pharmacies have been 
grouped into five new chains. There were also a few actors that have entered the 
market without acquiring any state-owned pharmacies, but many of them quickly 
realized that the prospects of reaching profitability were bleak. Before privatization, all 
945 pharmacies in the country were operated by one state-owned company, 
Apoteket AB. 615 of them were sold, while 330 stayed with Apoteket AB. "Apoteket" 
means "The Pharmacy", and Apoteket AB holds a trademark on the definite form of 
the Swedish word for pharmacy ("Apoteket"), while the indefinite form ("apotek") can 
be used by anyone. Hence, almost all new entrants have included the word "apotek" 
in their name. They have also gone for remarkably similar visual adenitis, with most 
of them using green as signature colour and some variation of a green cross as their 
symbol (http://brandingsource.blogspot.no/2011/07/swedish-pharmacies.html, 2014) 
3. Denmark 
In Denmark,  there is  a National health insurance system which depending on two 
types of reimbursement :general reimbursement and individual reimbursement, both 
of them are decided by the Danish Medicines Agency .In Denmark, there is a 
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relationship between the size of reimbursement and the patient’s total annual 
expenditure for reimbursable pharmaceuticals, age  and reimbursement 
threshold .Variation between 50%, 60%, 75%, 85% and 100%. Se web link for more 
information’s 
http://sundhedsstyrelsen.dk/en/medicines/reimbursement/reimbursement-thresholds . 
According to (http://whocc.goeg.at/Publications/CountryReports, 2014). 
Figure. 4 A chart for pharmaceutical system in Denmark (se web link below) 
 
http://whocc.goeg.at/Downloads/Conference2011/PraesentationenPPRIKonferenz/ge
neral_PPRI%20conference%202011%20Country%20poster%20book.pdf. 
4. Iceland 
The parliament in Iceland passes legislations concerning the national health 
insurance, and the ministry of welfare builds 0n these when deciding on co-payment 
structure. The main goal of a new act, passed in 2012, is to increase equality 
between individuals, regardless of diseases, and reduce medicinal costs for those 
having to use a lot of medicinal products. The pharmaceutical co-payment system in 
Iceland is construct red around stepwise co-payment, where each individual pays 
proportionally less as his or her costs because of medicinal products increase during 
a 12-month period. In the first step an individual pays the full cost of a medicinal 
product; in the second step 15% of the cost of medicines and in the third step 7.5%. 
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When the cost of medicines reaches a certain maximum, a doctor can apply to the 
National Health Insurance to fully pay the costs of medicine for the remainder of the 
period, after specified conditions are fulfilled. All of the medicines entitled to(Icelandic 
health insurance, SÍ)'s contributions to the payment of (including medicines an 
individual has gotten approved medicinal product certificates for) will be included in 
the payment steps. The medicinal products that SÍ does not contribute to paying, fall 
outside the payment stepsister the web link for more information’s: 
http://www.sjukra.is/english/social-insurance-in-iceland/medicinal-products/ 
Figure.5 A chart for pharmaceutical system in Iceland (se web link below) 
 
Source: 
http://whocc.goeg.at/Downloads/Conference2011/PraesentationenPPRIKonferenz/ge
neral_PPRI%20conference%202011%20Country%20poster%20book.pdf.    
5. Finland  
In Finland ,the Pharmaceutical pricing Board is the decision maker for pricing ,they 
use the international pricing system and working under the Ministry for Social Affairs 
and Health. The reimbursement system comprises three reimbursement categories: 
the basic refund category (with 42% of the full price reimbursed) and the lower and 
higher special reimbursement categories (72% and 100% reimbursed, respectively). 
The categories are set according to the severity of the treated condition and the 
153 
 
necessity of the drug treatment. A total of ten conditions are included in the lower 
category and 34 in the higher category. If a patient’s medicine expenses exceed a 
pre-set amount in a calendar year (€675.39 in 2011), the patient pays a fixed non-
reimbursable sum of 1.50 € for each reimbursable medicinal product purchased.  
(http://whocc.goeg.at/Publications/CountryReports, 2014). 
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